



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/12, C07K 14/725, 16/28, C12N 15/85, 5/10, A61K 35/14, 35/28, 48/00, C12N 15/62, C07K 19/00 // C12N 15/86	A1	(11) International Publication Number: <b>WO 96/30516</b> (43) International Publication Date: 3 October 1996 (03.10.96)
---	----	---

(21) International Application Number: PCT/US96/04143

(22) International Filing Date: 27 March 1996 (27.03.96)

(30) Priority Data:  
08/411,098 27 March 1995 (27.03.95) US

(71) Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Institutes of Health, Suite 325, 3011 Executive Boulevard, Rockville, MD 20852 (US).


(72) Inventors: HWU, Patrick; 11419 Commonwealth Drive #202, Rockville, MD 20852 (US). NISHIMURA, Michael; 16741 Cashell Road, Rockville, MD 20853 (US). ROSENBERG, Steven, A.; 10104 Iron Gate Road, Potomac, MD 20854 (US).

(74) Agent: FEILER, William, S.; Morgan &amp; Finnegan, L.L.P., 345 Park Avenue, New York, NY 10154 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published***With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: T-CELL RECEPTORS AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC METHODS



## (57) Abstract

The present invention provides nucleic acid sequences for T-cell receptors which recognize tumor associated antigens. In particular, T-cell receptors which recognize melanoma antigens. This invention also provides T-cells expressing the antigen specific T-cell receptors. In addition, this invention provides stem cells expressing the antigen specific T-cell receptors or chimeric receptors. This invention further relates to therapeutic and diagnostic compositions and methods employing the T-cell receptors and chimeric receptors provided herein.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE OF THE INVENTION

T-CELL RECEPTORS AND THEIR USE IN  
THERAPEUTIC AND DIAGNOSTIC METHODS

FIELD OF THE INVENTION

The field of the present invention relates generally to compositions and methods for the treatment or prevention of diseases in mammals. More specifically, this invention relates to T-cell receptors and chimeric receptors that recognize tumor associated antigens and to preventative, diagnostic and therapeutic applications which employ these T-cell receptors.

BACKGROUND OF THE INVENTION

Classic modalities for the treatment of diseases such as human cancers, autoimmune diseases, viral, bacterial, parasitic and fungal diseases include surgery, radiation chemotherapy, antibiotics or combination therapies. However, these therapies are not effective against a majority of these diseases. Alternate therapies for preventing or treating human diseases are greatly needed. In the past decade immunotherapy and gene therapy utilizing T-lymphocytes have emerged as new and promising methods for treating human disease, in particular human cancers.

T-cells play an important role in tumor regression in most murine tumor models. Tumor infiltrating lymphocytes (TIL) that recognize unique cancer antigens can be isolated from many murine tumors. The adoptive transfer of these TIL plus interleukin-2 can mediate the regression of established lung and liver metastases (Rosenberg, S.A., et al., (1986) Science 233:1318-1321). In addition, the secretion of IFN- $\gamma$  by injected TIL significantly correlates with in vivo regression of murine tumors suggesting activation of

- 2 -

T-cells by the tumor antigens. (Barth, R.J., et al., (1991) J. Exp. Med. 173:647-658). The known ability of TIL to mediate the regression of metastatic cancer in 35 to 40% of melanoma patients when adoptively transferred into patients with metastatic melanoma attests to the clinical importance of the antigens recognized (Rosenberg, S.A., et al., (1988) N Engl J Med 319:1676-1680; Rosenberg S.A. (1992) J. Clin. Oncol. 10:180-199).

T-cell receptors on CD8<sup>+</sup> T-cells recognize a complex consisting of an antigenic peptide (9-10 amino acids for HLA-A2),  $\beta$ -2 microglobulin and class I major histocompatibility complex (MHC) heavy chain (HLA-A, B, C, in humans). Peptides generated by digestion of endogenously synthesized proteins are transported into the endoplasmic reticulum, bound to class I MHC heavy chain and  $\beta$ 2 microglobulin, and finally expressed in the cell surface in the groove of the class I MHC molecule.

Strong evidence that an immune response to cancer exists in humans is provided by the existence of tumor reactive lymphocytes within melanoma deposits. These lymphocytes, when isolated, are capable of recognizing specific tumor antigens on autologous and allogeneic melanomas in an MHC restricted fashion. (Itoh, K. et al. (1986), Cancer Res. 46: 3011-3017; Muul, L.M., et al. (1987), J. Immunol. 138:989-995); Topalian, S.L., et al., (1989) J. Immunol. 142: 3714-3725; Darrow, T.L., et al., (1989) J. Immunol. 142: 3329-3335; Hom, S.S., et al., (1991) J. Immunother. 10:153-164; Kawakami, Y., et al., (1992) J. Immunol. 148: 638-643; Hom, S.S., et al., (1993) J. Immunother. 13:18-30; O'Neil, B.H., et al., (1993) J. Immunol. 151: 1410-1418). TIL from patients with metastatic melanoma recognize shared antigens including melanocyte-melanoma lineage specific tissue antigens in vitro (Kawakami, Y., et al., (1993) J. Immunother. 14: 88-93; Anichini, A. et al., (1993) et al., J. Exp. Med. 177: 989-998). Anti-melanoma T-cells appear



- 3 -

to be enriched in TIL probably as a consequence of clonal expansion and accumulation at the tumor site in vivo (Sensi, M., et al., (1993) J. Exp. Med. 178:1231-1246). The transduction of T-cells with a variety of genes, such as cytokines, has been demonstrated. T-cells have been shown to express foreign gene products. (Blaese, R.M., Pediatr. Res., 33 (1 Suppl):S49-S53 (1993); Hwu, P., et al. J. Immunol., 150:4104-415 (1993); Culver, L., et al. Proc. Natl. Acad. Sci. USA, 88:3155-3159 (1991)) The fact that patients mount cellular and humoral responses against tumor associated antigens suggests that identification and characterization of additional tumor antigens will be important for immunotherapy of patients with cancer.

#### SUMMARY OF THE INVENTION

This invention relates, in general, to nucleic acid and amino acid sequences for T-cell receptors which recognize or bind tumor associated antigens and to compositions and methods employing the same. In particular to the amino acid and nucleic acid sequences for the Variable-Joining (V/J) or Variable-Diversity-Joining (V/D/J) junctional sequences for the antigen specific T-cell receptors described herein. This invention further provides therapeutic uses for the nucleic acid and amino acid sequences for the T-cell receptors. It is also an object of this invention to provide T-cells or hematopoietic stem cells carrying these T-cell receptors or chimeric receptors and methods of using the same.

It is an object of this invention to provide isolated nucleic acid sequences encoding for T-cell receptors or parts thereof which recognize tumor associated antigens.

It is an object of this invention to provide amino acid sequences for T-cell receptors or parts thereof which recognize or bind tumor associated antigens.

- 4 -

It is another object of this invention to provide isolated nucleic acid sequences of T-cell receptors which recognize melanoma antigens.

5 It is another object of this invention to produce recombinant molecules encoding for all or parts thereof for the T-cell receptors that recognize tumor associated antigens.

10 It is another object of this invention to provide methods of detecting nucleic acid sequences encoding the antigen specific T-cell receptors.

It is another object of this invention to provide diagnostic methods for human disease, in particular for cancers.

15 It is yet another object of this invention to provide a chimeric receptor comprising an antibody variable region joined to the cytoplasmic region of CD28 from a T cell or a similar region which can provide a T cell with costimulation signals.

20 It is a further object of this invention to provide methods for prophylactic or therapeutic uses involving all or part of the nucleic acid sequence or amino acid sequences for the T-cell which recognize tumor associated antigens.

25 It is also an object of this invention to provide compositions and methods for immunotherapy employing hematopoietic stem cells or T-cells carrying the T-cell receptors or chimeric receptors.

30 In addition, it is another object of this invention to provide combination therapies comprising all or part of the nucleic acid sequences described herein and other T-cell receptors that recognize tumor associated antigens.

35 It is another object of this invention to provide a method of prophylactic or therapeutic treatment of cancers using the methods described herein.

It is a further object of this invention to provide T-cells or hematopoietic stem cells carrying receptors that recognize cancer antigens for use in immunotherapy.

#### DESCRIPTION OF THE FIGURES

Figures 1A-1B show TCR $\alpha$  and TCR $\beta$  junctional sequences from melanoma specific cytotoxic T lymphocyte (CTL) clones. Figure 1A shows that Clone C10-1 contains one functional TCR $\alpha$  transcript and one in frame TCR $\beta$  transcript. Although the V $\alpha$  14.1/J $\alpha$ 32/C $\alpha$  transcript was in frame, the N (N diversity region) region sequence produced a frame shift in J $\alpha$ 32 resulting in the loss of the highly conserved FGXG structural motif (Koop, et al. (1993) *Genomics* 84:478-493). Splicing at an alternative site at the 3' end of the J $\alpha$ 32 segment resulted in the restoration of the reading frame in the C region. The TCR $\alpha$  gene using V $\alpha$ 8.2/J $\alpha$ 49/C $\alpha$  and the TCR $\beta$  gene were productively rearranged. Boxes indicate the 3' ends of the V genes and the 5' ends of the C regions. The TCR $\alpha$  and TCR $\beta$  parts of the J regions is underlined. The N regions are unmarked. Only the 5' end of the constant region is shown. Figure 1B shows the alignment of the TCR $\alpha$  and TCR $\beta$  junctional sequences from three HLA-A2 restricted TIL. The amino acid sequence for each J region matches the sequence reported for other transcripts using the same J region. No DNA or amino acid sequence homology was observed in the N regions. Only the 5' end of the constant region is shown.

Figure 2 shows TCR  $\alpha$  and TCR  $\beta$  junctional sequences from MART-1 epitope M9-2 specific cytotoxic T-lymphocyte clones. The 3' ends of the V genes and the 5' ends of the C regions are labeled. Germline J regions are underlined, and the N regions are unmarked. The amino acid sequence for each J region matches the sequence

- 6 -

reported for other transcripts using the same J region.  
Only the 5' end of the constant region is shown.

Figures 3A to 3C shows immunofluorescence analysis of clone 5 TCR-transfected (bulk, clone 13, and clone 22) and nontransfected (neo) Jurkat cell lines. Jurkat transfectants ( $1 \times 10^6$ ) were incubated for 12 h at 37°C with (represented by solid-line histograms) or without (represented by dotted-line histograms) 100  $\mu$ l of Jurkat TCR  $\beta$  chain-specific mAb C305.2 supernatant. All four cell lines were then restained with: Figure 3A anti-CD3 mAb; Figure 3B pan-specific anti-TCR-1 mAb; and Figure 3C C305.2 mAb (to verify the down-modulation of endogenous TCR).

Figure 4 shows graphic representation of IL-2 production by clone 5 TCR transfected (bulk, clone 13, and clone 22) Jurkat cell lines at varying levels of peptide concentration. The sensitivity of Jurkat TCR transfectant response to antigen stimulation was assessed by performing a series of 5X serial dilutions of the immunodominant M9-2 peptide (starting with a maximum concentration of 50 mM) pulsed on T2 cells and subsequently evaluating the ability of the T2 cells to mediate IL-2 release from the Jurkat cells. Relative sensitivity was determined from determining the concentration of peptide required to attain 50% of maximal cytokine response.

Figure 5 shows the chimeric antibody/T-cell receptor which allows TCR signal transduction via antibody-antigen recognition. Single-chain antibody variable regions (scFv) are joined to TCR signaling chains, such as the  $\gamma$  chain of the Fc receptor, which shares homology with the TCR- $\zeta$  chain and is capable of mediating TCR signal transduction (Orloff, D., et al. Nature, 347: 189-191, 1990, Letourneur, F. and Klausner, R.D. Proc Natl Acad Sci USA, 88: 8905-8909, 1991, Romeo, C., et al. Cell, 68: 889-897, 1992, Romeo, C. and Seed, B.

- 6/1 -

reported for other transcripts using the same J region. Only the 5' end of the constant region is shown.

Figures 3A to 3L show immunofluorescence analysis of clone 5 TCR-transfected [bulk (Figures 3B, 3F and 3J), clone 13 (Figures 3C, 3G and 3K), and clone 22 (Figures 3D, 3H and 3L)] and nontransfected [neo (Figures 3A, 3E and 3I)] Jurkat cell lines. Jurkat transfectants ( $1 \times 10^6$ ) were incubated for 12 h at 37°C with (represented by *solid-line* histograms) or without (represented by *dotted-line* histograms) 100  $\mu$ l of Jurkat TCR  $\beta$  chain-specific mAb C305.2 supernatant. All four cell lines were then restained with: Figures 3A-3D anti-CD3 mAb; Figures 3E-3H pan-specific anti-TCR-1 mAb; and Figures 3I-3L C305.2 mAb (to verify the down-modulation of endogenous TCR).

Figure 4 shows graphic representation of IL-2 production by clone 5 TCR transfected (bulk, clone 13, and clone 22) Jurkat cell lines at varying levels of peptide concentration. The sensitivity of Jurkat TCR transfectant response to antigen stimulation was assessed by performing a series of 5X serial dilutions of the immunodominant M9-2 peptide (starting with a maximum concentration of 50 mM) pulsed on T2 cells and subsequently evaluating the ability of the T2 cells to mediate IL-2 release from the Jurkat cells. Relative sensitivity was determined from determining the concentration of peptide required to attain 50% of maximal cytokine response.

Figures 5A-5C show the chimeric antibody/T-cell receptor which allows TCR signal transduction via antibody-antigen recognition. Figure 5A represents the antibody, Figure 5B represents the TCR and Figure 5C represents scFv- $\gamma$ . Single-chain antibody variable regions (scFv) are joined to TCR signaling chains, such as the  $\gamma$  chain of the Fc receptor, which shares homology with the TCR- $\zeta$  chain and is capable of mediating TCR signal transduction (Orloff, D., et al. Nature, 347: 189-191,

- 6/2 -

1990, Letourneur, F. and Klausner, R.D. Proc Natl Acad Sci  
USA, 88: 8905-8909, 1991, Romeo, C., et al. Cell, 68:  
889-897, 1992, Romeo, C. and Seed, B.

- 7 -

Cell, 64: 1037-1046, 1991, Irving, B.A. and Weiss, A.  
Cell, 64: 891-901, 1991).

5                   Figures 6A to 6D show FACS analysis with MoAb  
MOV18 to determine expression of folate binding protein  
(FBP) on various tumor lines. IGROV-1 is a human ovarian  
carcinoma (Figure 6C). 24JK is a clone of the poorly-  
immunogenic methylcholanthrene induced murine sarcoma MCA-  
102 (Figure 6B). 24JK cells were retrovirally transduced  
10                   with a vector containing the FBP gene to generate the  
24JK-FBP cell line (Figure 6D). 888 MEL is a human  
melanoma cell line (Figure 6A). (Open graph = control  
antibody; Shaded graph = MOV18 antibody; y-axis =  
relative number of cells; x-axis = log fluorescence  
intensity)

15                   Figure 7 shows appearance of lungs at 11 days  
after injection of 24JK-FBP cells. On day 3 after tumor  
injection, mice began therapy with either IL-2 (upper  
left), unmodified TIL + IL-2 (upper right), or MOV- $\gamma$   
transduced TIL + IL-2 (lower) as described in Materials  
20                   and Methods of Example 4. Lungs were harvested after  
injection of india ink into trachea. Lungs were bleached  
with Fekete's solution to produce white metastases on a  
black background. A substantial reduction in metastases  
was seen in mice receiving MOV- $\gamma$  transduced TIL + IL-2,  
25                   compared to the other groups.

                  Figure 8 shows histopathologic evaluation of  
peritoneal cavity 3 days following intraperitoneal  
injection of  $2.5 \times 10^6$  human ovarian cancer IGROV cells into  
nude mice. Ovarian cancer cells can be seen invading the  
30                   murine omentum.

                  Figure 9 shows survival of nude mice following  
intraperitoneal injection with human ovarian cancer  
(IGROV) cells. On day 3 following tumor injection (see  
Figure 8, for histopathologic evaluation on day 3), mice  
35                   were treated with HBSS, unmodified (NV) murine TIL, or TIL  
transduced with either the MOV- $\gamma$  receptor or the control  
Sp- $\gamma$  receptor (MOV-TIL and TNP-TIL, respectively). Mice

- 8 -

treated with MOV-TIL demonstrated a significant increase in survival compared to the other groups.

Figures 10A-10B show retroviral constructs LMov $\gamma$ EN (Figure 10A) and LPMov $\gamma$  (Figure 10B) containing receptor genes, used to transduce hematopoietic stem cells.

#### DETAILED DESCRIPTION OF THE INVENTION

For the purpose of a more complete understanding of the invention, the following definitions are described herein. Nucleic acid sequences include, but are not limited to, DNA, RNA or cDNA. Substantially homologous as used herein refers to substantial correspondence between the nucleic acid sequence for the V-J or V-D-J junctional sequences for the  $\alpha$  and  $\beta$  chains of the tumor antigen specific T-cell receptors provided herein and that of any other nucleic acid sequence. By way of example, substantially homologous means about 50-100% homology, preferably by about 70-100% homology, and most preferably about 90-100% homology between the nucleic acid sequences and that of any other nucleic acid sequence. In addition, substantially homologous as used herein also refers to substantial correspondences between the amino acid sequence of the V-J or V-D-J junctional sequences of the antigen specific T-cell receptors provided herein and that of any other amino acid sequence.

Major Histocompatibility Complex (MHC) is a generic designation meant to encompass the histocompatibility antigen systems described in different species including the human leucocyte antigens (HLA). The term cancer includes but is not limited to, melanoma, epithelial cell derived cancers, lung cancer, colon cancer, ovarian cancer, breast cancer, kidney cancer, prostate cancer, brain cancer, or sarcomas.

Such cancers in mammals may be caused by, chromosomal abnormalities, degenerative growth and developmental disorders, mitogenic agents, ultraviolet



radiation (UV), viral infections, inappropriate tissue expression of a gene, alterations in expression of a gene, or carcinogenic agents. The term melanoma includes, but is not limited to, melanomas, metastatic melanomas, melanomas derived from either melanocytes or melanocyte related nevus cells, melanocarcinomas, melanoepitheliomas, melanomasarcomas, melanoma in situ, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, invasive melanoma or familial atypical mole and melanoma (FAM-M) syndrome. The aforementioned cancers can be treated, assessed or diagnosed by methods described in the present application.

T lymphocytes recognize antigen in the form of peptide fragments that are bound to class I and class II molecules of the major histocompatibility complex (MHC) locus. The T-cell receptor for antigen (TCR) is a complex of at least 8 polypeptide chains. ("Basic and Clinical Immunology" (1994) Stites, Terr and Parslow(eds) Appleton and Lange, Nenmack Conn.) Two of these chains (the  $\alpha$  and  $\beta$  chains) form a disulfide-linked dimer that recognizes antigenic peptides bound to MHC molecules and therefore is the actual ligand-binding structure within the TCR. The TCR  $\alpha$  and  $\beta$  chains are similar in many respects to immunoglobulin proteins. The amino-terminal regions of the  $\alpha$  and  $\beta$  chains are highly polymorphic, so that within the entire T-cell population there are a large number of different TCR  $\alpha/\beta$  dimers, each capable of recognizing or binding a particular combination of antigenic peptide and MHC.

The  $\alpha/\beta$  dimer is associated with a complex of proteins designated CD3. The CD3 molecules are involved in signal transduction by allowing the TCR to convert the recognition of antigen/MHC into intracellular signals for transduction.

To generate the diversity of TCR required to recognize a wide spectrum of antigenic determinants, the

- 10 -

TCR  $\alpha$  and  $\beta$  genes use a combinatorial strategy of DNA rearrangement similar to that of the immunoglobulin genes. The germline TCR  $\beta$  gene contains about 65 V (variable), 2 D (diversity), 13 J (joining) gene segments and 2 C (constant regions segments). When the TCR  $\beta$  gene rearranges early in T-cell development, one of the  $V_\beta$  region segments becomes linked to one of the  $D_\beta$  regions and to one of the  $J_\beta$  segments to form a single transcriptional unit. The V-D-J splices to a constant  $C_\beta$  (constant) region to form a TCR  $\beta$  mRNA that encodes a functional protein. Great diversity is generated by this combinatorial joining. In the TCR  $\alpha$  locus, there are greater than 45-50 segments V segments and about 60 J segments, one C segment but no D segments. To form a functional TCR  $\alpha$  chain gene, a  $V_\alpha$  segment joins to a  $J_\alpha$  segment and the V-J transcript splices to a constant region ( $C\alpha$ ).

Diversity is further enhanced by imprecise joining of the gene segments and/or by the insertion of non-germline-encoded nucleotides (designated N regions) between segments during the rearrangement process. These mechanisms generate junctional diversity, in particular the diversity of sequences at the junctions between  $V_\alpha$  and  $J_\alpha$  and between  $V_\beta$ ,  $D_\beta$ , and  $J_\beta$  segments. The V-J and V-D-J junctional sequences are unique to each T-cell receptor clonotype and contribute to the T-cell receptor diversity

In accordance with the present invention, amino acid sequences are provided for the V-J or V-D-J junctional regions or parts thereof for the alpha and beta chains of the T-cell receptor which recognize tumor associated antigens. In general, this invention relates to T-cell receptors which recognize or bind tumor associated antigens presented in the context of MHC Class I. In a preferred embodiment the tumor associated antigens recognized by the T-cell receptors of this invention are melanoma antigens. By way of example the

- 11 -

melanoma specific T-cell receptors of this invention may recognize melanoma antigens in the context of HLA-A2.1 or HLA-A1. Examples of melanoma antigens which are recognized by the T-cell receptors include, but are not limited to, MART-1, or peptides thereof or gp-100 or peptides thereof. In a preferred embodiment the T-cell receptor recognizes or binds to the MART-1 peptide, in particular epitopes M9-1 (TTAEAAAGI), M9-2 (AAGIGILTV), M10-3 (EAAGIGILTV), and M10-4 (AAGIGILTVI) (shown in single letter amino acid code, Examples 2 and 3) or gp-100 peptide epitopes.

The functional  $\alpha$  chain of the heterodimeric T-cell receptors of this invention may have the following formula:

V-J-C

wherein,

V is an amino acid sequence comprising the variable region of the  $\alpha$  chain. By way of example, the V gene after rearrangement may have a 3' end encoding for a carboxy terminus sequence of Cysteine-Xaa<sub>n</sub>, where n may be about 1-5 and Xaa may be any amino acid or a combination of amino acids. Preferably Xaa is Alanine or Serine. In a preferred embodiment, the 3' end of the V gene encodes for a carboxy terminus of Cysteine - Alanine. Preferred carboxy terminus for the V  $\alpha$  gene are shown in Figures 1A and 1B and Figure 2. Examples of V $\alpha$  genes that be may be used in generating this region include, but are not limited to, V $\alpha$  8.2 or V $\alpha$ 17, V $\alpha$ 9, V $\alpha$ 1, V $\alpha$ 25, or V $\alpha$ 21.

J denotes the joining region. Examples of J genes that may be used to generate this region, include but are not limited to, J $\alpha$ 49, J $\alpha$ 42, J $\alpha$ 16, or J $\alpha$ 54. In addition the J region may also contain N regions as shown in Figures 1A-1B and 2. Preferred J regions for the  $\alpha$  chains of the T-cell receptor of this invention are shown in Figure 1A and 1B and Figure 2. C denotes the constant region of the  $\alpha$  chain.

- 12 -

Preferred V-J junctional sequences for the T-cell receptors of this invention are shown in Figures 1A-1B and Figure 2.

The functional  $\beta$  chain of the heterodimer T-cell receptors may have the formula:

V-D-J-C

wherein

V is an amino acid sequence comprising the variable region of the  $\beta$  chain. The V gene may have a 3' end encoding for a carboxy terminus of Cysteine-Xaa<sub>n</sub>, wherein n may be about 1-5 and Xaa may be any amino acid or combination of amino acids. Preferably, Xaa is either Alanine or Serine. In a preferred embodiment, the 3' end of the V region encodes for a carboxy terminus of Cysteine - Alanine - Serine, or Cysteine - Alanine - Serine - Serine, or Cysteine-Alanine. Preferred carboxy termini for the V $\beta$  region are shown in Figure 1A - Figure 1B and Figure 2. Examples of V genes that may be used for the V region include but are not limited to V $\beta$ 13.6, V $\beta$ 6.5, V $\beta$ 22.1, V $\beta$ 7.3, or V $\beta$ 3.1.

J denotes the joining region. Examples of J $\beta$  genes that may be used in generating the joining regions include, but are not limited to, J $\beta$ 1.5, J $\beta$ 2.1, J $\beta$ 1.1, or J $\beta$ 2.7. The joining region may also contain N regions as shown in Figures 1A-1B and Figure 2. Examples of D (diversity) genes that may be used include, but are not limited to D $\beta$ 1.1, or D $\beta$ 2.1.

C denotes the constant regions of the  $\beta$  chain. Examples of constant regions that may be used, include, but are not limited to C $\beta$ 1 in C $\beta$ 2. Preferred V-D-J junctional sequences for the  $\beta$  chain of the T-cell receptors provided herein are shown in Figures 1A-1B and Figure 2.

In one embodiment the T-cell receptor of this invention comprises an  $\alpha$  chain comprising a nucleic acid sequence encoding for a variable region having a 3'

- 13 -

encoding for a carboxy terminus of Cysteine-Xaa<sub>n</sub>, a J region and a constant region in combination with a  $\beta$  chain comprising a nucleic acid sequence encoding for a variable region having a 3' end encoding for carboxy terminus of Cysteine Xaa<sub>n</sub>, a D region and a J region and a constant region. The alpha and beta chains of the T-cell receptors form a ligand binding domain that preferably recognizes a tumor associated antigen, most preferably melanoma antigens.

In the preferred embodiments the melanoma specific T-cell receptors provided herein have the following  $\alpha$  and  $\beta$  chain combinations, the tumor infiltrating lymphocyte C10-1 T-cell clonotype comprising the V $\alpha$  8.2/J $\alpha$  49/C $\alpha$  chain (SEQ. ID NOS: 1 AND 14), having the V-J junctional sequences shown in Figure 1A and V $\beta$ 13.6/D $\beta$ 1.1/J $\beta$ 1.5/C $\beta$ 1 (SEQ. ID NOS: 3 AND 16) having the V-D-J junctional sequences shown in Figure 1A; the TIL F2-2 clonotype comprising V $\alpha$  17/J $\alpha$ 42/C $\alpha$  (SEQ. ID NOS: 4 AND 17) having the V-J junctional sequences shown in Figure 1B and V $\beta$ 6.5/D $\beta$ 1.1/J $\beta$ 1.5/C $\beta$ 1 (SEQ. ID NOS: 7 AND 20) having the V-D-J junctional sequences shown in Figure 1B; the TIL 1200 clonotype comprising V $\alpha$ 9/J $\alpha$ 16/C $\alpha$  (SEQ. ID NOS: 5 AND 18) having the V-J junctional sequences shown in Figure 1B and V $\beta$ 22.1/D $\beta$ 2.1/J $\beta$ 2.1/C $\beta$ 2 (SEQ. ID NOS: 8 AND 21) having the V-D-J junctional sequences shown in Figure 1B; TIL5 clonotype comprising V $\alpha$ 1/J $\alpha$ 49/C $\alpha$  (SEQ. ID NOS: 6 AND 19) having the V-J junctional sequences shown in Figure 1B; and V $\beta$ 7.3/D $\beta$ 2.1/J $\beta$ 2.1/C $\beta$ 2 (SEQ. ID NOS: 9 AND 22) having the V-D-J junctional sequences shown in Figure 1B; the TIL 1E2 clonotype comprising V $\alpha$ 25/J $\alpha$ 54/C $\alpha$  (SEQ. ID NOS: 10 AND 23) having the V-J junctional sequences shown in Figure 2 and V $\beta$ 3.1/D $\beta$ 1.1/J $\beta$ 1.1/C $\beta$ 1 (SEQ. ID NOS: 12 AND 25) having the V-D-J junctional sequences shown in Figure 2; or the TIL A42 clonotype comprising V $\alpha$ 21/J $\alpha$ 42/C $\alpha$  (SEQ. ID NOS: 11 AND 24) having the V-J junctional sequences shown in Figure 2 and V $\beta$ 7.3/D $\beta$ 2.1/J $\beta$ 2.7/C $\beta$ 2 (SEQ. ID NOS:

- 14 -

13 AND 26) having the V-D-J junctional sequences shown in Figure 2.

The T-cell receptors of this invention may be naturally occurring or synthetically produced. The  $\alpha$  and  $\beta$  chains that comprise the T-cell receptors of this invention may be produced by standard recombinant methodology known to those skilled in the art. The GENBANK Accession Numbers for examples of the  $V\alpha$ ,  $J\alpha$ ,  $C\alpha$ ,  $V\beta$ ,  $D\beta$  and  $J\beta$  genes that may be used in constructing the  $\alpha$  and  $\beta$  chains of the T-cell receptors of this invention are provided below. These genes may be used as the framework for inserting the unique J-V or J-D-V junctional sequences provided herein for the T-cell receptors of this invention.

- 15 -

**Sequences of V $\alpha$  Genes  
Used by Cytotoxic Lymphocyte Clones**

5	<u>TIL Clone</u>	<u>Gene</u>	<u>Genbank Name</u>	<u>Accession Number</u>	<u>Clone Name</u>
	TIL5	V $\alpha$ 1	HUMTCRAVG	L06885	
		V $\alpha$ 1	HSTCRA031	X58769	IGRa08
10		V $\alpha$ 1	HUMTCAZC	M17668, J02992	AE11
	TIL 1200	V $\alpha$ 9	HSTCRA08	X04942	HAVP36
			HUMTCAXU	M13737	HAP36
			HUMTCRAAD	M90479	CTL5A2
15	TIL C10-1	V $\alpha$ 8.2	HUMTCAXT	M13736	HAP50
	TIL F2-2	V $\alpha$ 17	HUMTCVJCA	M97704	IGRa05
			HSTCRVAE	X70309	HTA61
	TIL A42	V $\alpha$ 21	HUMTCAYE	M15565	L17
	TIL 1E2	V $\alpha$ 25	HSTRA003	X58738	IGRa03

20

25

30

35

- 16 -

Sequences of  $J\alpha$ ,  $C\alpha$ ,  $V\beta$ ,  $D\beta$ ,  $J\beta$   
and  $C\beta$  Genes Used By CTL Clones

	<u>Gene</u>	<u>Genbank Name</u>	<u>Accession Number</u>
5	$J\alpha 1$ through $J\alpha 60$	HUMTCRADCV	M94081
	$C\alpha$	HUMTCRAC	X02883
	$V\beta 1.1$ through $V\beta 25.1$	HUMTCRB	L36092
	$D\beta 1$ , $J\beta 1.1$ through $J\beta 1.6$	HUMTCBJC	M14158
10	$D\beta 2$ , $J\beta 2.1$ through $\beta 2.7$	HUMTCBJD	M14159
	$C\beta 1$	HUMTCBCB	M14157
	$C\beta 2$	HUMTCBCC	M12510

15

20

25

30

35



- 17 -

This invention further includes the T-cell receptors or analogs thereof having substantially the same function or activity as the T-cell receptors of this invention which recognize or bind tumor associated antigens, in particular melanoma antigens. Such receptors or proteins include, but are not limited to, a fragment of the protein, or a substitution, addition or deletion mutant of the T-cell receptors provided herein. This invention also encompasses proteins or peptides that are substantially homologous to the T-cell receptors provided herein or retain the same activity. The term "analog" includes any protein or polypeptide having an amino acid residue sequence substantially identical to the T-cell receptors provided herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the functional aspects of the T-cell receptor as described herein. By way of example, such receptors may recognize the tumor associated antigens, MART-1 or gp100 or peptides derived therefrom. Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid or another.

The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue. "Chemical derivative" refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. Examples of such derivatized molecules include for example, those molecules in which

- 18 -

free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those proteins or peptides which contain one or more naturally-occurring amino acid derivatives of the twenty standard amino acids. For examples: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. Proteins or polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions or residues relative to the sequence of a polypeptide whose sequence is encoded by the DNA sequences of the receptor, so long as the requisite activity is maintained. The nucleic acid sequences for the tumor antigen specific T-cell receptors provided herein represent a preferred embodiment of the invention. It is however, understood by one skilled in the art that due to the degeneracy of the genetic code variations in the nucleic acid sequences may still result in a sequence capable of encoding the tumor antigen specific T-cell receptor. Such sequences are therefore functionally equivalent to the sequences set forth here. Nucleic acid sequences which encode for a tumor antigen T-cell receptor having the functional activity of that receptor are also intended to be encompassed by this invention.

This invention also provides a recombinant DNA molecule comprising all or part of the T-cell receptor

- 19 -

o

nucleic acid sequences provided herein and a vector. The nucleic acid sequences encoding the  $\alpha$  and  $\beta$  chains of a T-cell receptor of the present invention may be placed in a single expression vector. Alternatively the  $\alpha$  chain and the  $\beta$  chain may each be placed in a separate expression vector. Expression vectors suitable for use in the present invention may comprise at least one expression control element operationally linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence. Examples of expression control elements include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus, cytomeglia virus (CMV), SR $\alpha$ , MMLV, SV40 or housekeeping promoters such as phosphoglycerol kinase (PGK) and  $\beta$  actin. Additional preferred or required operational elements include, but are not limited to, leader sequence, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in the host system. It will be understood by one skilled in the art the correct combination of required or preferred expression control elements will depend on the host system chosen. It will further be understood that the expression vector may contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers and long terminal repeats (LTR) and internal ribosomal entry site (IRES). The expression vector may also include a leader peptide sequence. It will further be understood by one skilled in the art that such vectors are easily constructed using conventional methods (Ausubel et al., (1987) in "Current

- 20 -

Protocols in Molecular Biology", John Wiley and Sons, New York, New York) or commercially available.

Another aspect of this invention relates to a host organism into which recombinant expression vector containing all or part of the nucleic acid sequences of the T-cell receptor of this invention has been introduced. The  $\alpha$  and  $\beta$  chains of the T-cells of this invention may be expressed independently in different hosts or in the same host. Preferably the  $\alpha$  and  $\beta$  chains are introduced into the same host to allow for formation of a functional T-cell receptor. The host cells transformed with all or part of the T-cell receptor nucleic acid sequences of this invention include eukaryotes, such as animal, plant, insect and yeast cells and prokaryotes, such as E. coli. By way of example animal cells may include JURKAT-cells, T-lymphocytes, peripheral blood cells, monocytes, stem cells, natural killer cells or macrophages. The means by which the vector carrying the gene may be introduced into the cell include, but are not limited to, microinjection, electroporation, transduction, retroviral transduction or transfection using DEAE-dextran, lipofection, calcium phosphate, particle bombardment mediated gene transfer or direct injection of nucleic acid sequences encoding the T-cell receptors of this invention or other procedures known to one skilled in the art (Sambrook et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York). The T-cell receptor produced by the expression vector may be isolated and purified and used in crystallography studies or for the generation of antibodies.

In a preferred embodiment, eukaryotic expression vectors that function in eukaryotic cells are used. Examples of such vectors include, but are not limited to, retroviral vectors, vaccinia virus vectors, adenovirus vectors, adeno associated virus (AAV) herpes virus vector, fowl pox virus vector, plasmids, such as pCDNA3

- 21 -

(Invitrogen, San Diego, CA) or the baculovirus transfer vectors. By way of example, eukaryotic expression vectors that may be used include, but is not limited to, GLEN (Treisman, J., et al., Blood, 85:139; Morgan, et al. (1992) Nucleic Acids, Res. 20:1293-1299), LXSN (Miller, A.D., et al. Methods Enzymol., 217:581-599 (1993); Miller, A.D., et al., BioTechniques, 7:980-988 (1989); Miller, A.D., et al. Mol. Cell. Biol., 6:2895-2902 (1986); Miller, A.D., Curr. Top. Microbiol. Immunol., 158:1-24 (1992)) or SAM-EN vectors (Treisman, J., et al. Blood, 85:139). Preferred eukaryotic cell lines include, but are not limited to, COS cells, CHO cells, HeLa cells, NIH/3T3 cells, 293 cells (ATCC# CRL1573), T2 cells, dendritic cells, monocytes, or JURKAT-cells. In a preferred embodiment the recombinant T-cell receptor protein expression vector is introduced into mammalian cells, such as NIH/3T3, COS-7, CHO, 293 cells (ATCC #CRL 1573), T2 cells, dendritic cells, T-cells, natural killer cells, hematopoietic stem cells or monocytes to ensure proper processing and modification of the receptor protein.

- 22 -

In one embodiment the expressed recombinant T-cell receptors may be detected by methods known in the art which include Coomassie blue staining and Western blotting using antibodies specific for the specific T-cell receptor. In a further embodiment, the recombinant protein expressed by the host cells can be obtained as a crude lysate or can be purified by standard protein purification procedures known in the art which may include differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity, and immunoaffinity chromatography and the like. (Ausubel et. al., (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York). In the case of immunoaffinity chromatography, the recombinant protein may be purified by passage through a column containing a resin which has bound thereto antibodies specific for the T-cell receptors of this invention (Ausubel et. al., (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York).

The nucleic acid sequence or portions thereof, of this invention are useful as probes for the detection of expression of the rearranged genes encoding for the T-cell receptors of this invention as well as the corresponding mRNA. Therefore, another aspect of the present invention relates to an assay for detecting messenger RNA or DNA encoding the T-cell receptors of this invention in a biological sample.

RNA can be isolated as whole cell RNA or as poly(A)<sup>+</sup> RNA. Whole cell RNA and polyA RNA can be isolated by a variety of methods known to those skilled in the art. (Ausubel et al., (1987) on "Current Protocols in Molecular Biology", John Wiley and Sons, New York). Standard methods for isolating DNA from a biological sample, detecting alterations in a gene and detecting complex between the nucleic acid probe and genomic DNA

sequences are provided in manuals such as Sambrook et al., (eds) (1989) "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York and in Ausubel et al., (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York. Conventional Methodology may be used to resolve and detect the mRNA or DNA (Sambrook et. al., (1989) in "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York; Ausubel et al., (1987) in "Current Protocols in Molecular Biology, John Wiley and Sons, New York New York). Standard techniques may be used to label the probes of this invention. Sambrook et al., (eds) (1989) "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York and in Ausubel et al., (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York. Radioactive and non-radioactive labelling kits are also commercially available.

Examples of biological samples that can be used in this bioassay include, but are not limited to, tissues such as lymph node, peripheral blood lymphocytes, tumor biopsies, bone marrow, lymphoid organs, biopsy specimens, such as melanoma, pathology specimens, and necropsy specimens. In a preferred embodiment, the nucleic sequence used as probes are derived from the J-V or J-D-V junctional sequences of the region of the  $\alpha$  or  $\beta$  chain comprising the T-cell receptors (Figures 1A-1B and Figure 2). Preferred nucleic acid sequences to be used as probes comprise or include the N region. Alternatively the full length or parts thereof of nucleic acid sequences provided herein may be used as probes.

In another embodiment, combinations of oligonucleotide pairs based on the J-V or J-D-V junctional sequences of the  $\alpha$  or  $\beta$  chains respectively shown in Figure 1A-1B and 2 may be used to derive Polymerase Chain Reaction (PCR) primers to detect the RNA or rearranged

- 24 -

germ line sequences in a biological sample. These primers can be used in a method following the reverse transcriptase - Polymerase Chain Reaction (RT-PCR) process for amplifying selected RNA nucleic acid sequences as detailed in Ausubel et al., (eds) (1987) In "Current Protocols in Molecular Biology" Chapter 15, John Wiley and Sons, New York, New York. The oligonucleotides can be synthesized by automated instruments sold by a variety of manufacturers or can be commercially prepared based upon the nucleic acid sequence of this invention. One skilled in the art will know how to select PCR primers based on the nucleic acid sequence for amplifying RNA or rearranged germline sequences DNA in a sample. Methods for the detection of the RNA or DNA encoding the T-cell receptors provided herein may be used to assess the efficacy of or determine the course of treatment for the therapeutic methods provided herein using the T-cells receptors.

In yet another embodiment of this invention all or parts thereof of the nucleic acid sequence for the antigen specific T-cell receptors provided herein can be used to generate transgenic animals. Preferably the sequences encoding  $\alpha$  and  $\beta$  the chains of the antigen specific T-cells of this invention are introduced into an animal or an ancestor of the animal at an embryonic stage, preferably at the one cell stage and generally not later than about the eight cell stage. There are several means by which transgenic animals carrying a T-cell receptor gene can be made. One method involves the use of retroviruses carrying all or part of the T-cell receptor sequences. The retroviruses containing the transgene are introduced into the embryonic animal by transfection. Another method involves directly injecting the transgene into the embryo. Yet another method employs the embryonic stem cell method or homologous recombination method known to workers in the field. Examples of animals into which the T-cell receptor transgene can be introduced include,



- 25 -

but are not limited to, non-human primates, mice, rats or other rodents. Such transgenic animals may be useful as biological models for the study of cancer and to evaluate diagnostic or therapeutic methods for the treatment of cancers in particular melanoma.

This invention further comprises an antibody or antibodies reactive with the T-cell receptor or parts thereof of this invention. In this embodiment of the invention the antibodies are monoclonal or polyclonal in origin. The antigen specific T-cell receptors or parts thereof used to generate the antibodies may be from natural or recombinant sources or generated by chemical synthesis. The natural T-cell receptors can be isolated from mammalian biological samples. Biological samples include, but is not limited to mammalian tissues such as peripheral blood lymphocytes (PBL), blood, lymphoid organs, lymph nodes, lymph nodes, T-cells, or biopsy samples, such as from melanoma. The natural proteins may be isolated by the same methods described above for recombinant proteins. Recombinant T-cell receptor proteins or peptides may be produced and purified by conventional methods. Synthetic peptides may be custom ordered, or commercially made or synthesized by methods known to one skilled in the art (Merrifield, R.B. (1963) J. Amer. Soc. 85:2149) based on the amino acid sequence of the invention. If the peptide is too short to be antigenic it may be conjugated to a carrier molecule to enhance the antigenicity of the peptide. Examples of carrier molecules, include, but are not limited to, human albumin, bovine albumin and keyhole limpet hemo-cyanin ("Basic and Clinical Immunology" (1991) Stites, D.P. and Terr A.I. (eds) Appleton and Lange, Norwalk, Connecticut, San Mateo, California).

Exemplary antibody molecules for use in the detection methods of the present invention are intact immunoglobulin molecules, substantially intact

- 26 -

immunoglobulin molecules or those portions of an immunoglobulin molecule that contain the antigen binding site, including those portions of immunoglobulin molecules known in the art as F(ab), F(ab'); F(ab)<sub>2</sub>, and F(v).

5 Polyclonal or monoclonal antibodies may be produced by methods known in the art. (Kohler and Milstein (1975) Nature 256, 495-497; Campbell "Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas" in Burdon et al. (eds.) (1985) 10 "Laboratory Techniques in Biochemistry and Molecular Biology," Volume 13, Elsevier Science Publishers, Amsterdam). The antibodies or antigen binding fragments may also be produced by genetic engineering. The technology for expression of both heavy and light chain 15 genes in E. coli is the subject of the following PCT patent applications: publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al. (1989) Science 246:1275-1281.

The antibodies of this invention may react with 20 native or denatured T-cell receptor protein or peptides or analogs thereof. The specific immunoassay in which the antibodies are to be used will dictate which antibodies are desirable. Antibodies may be raised against the native T-cell receptor proteins or portions thereof or 25 against synthetic peptides homologous to the unique regions of the amino acid sequence of the T-cell receptors.

In one embodiment the antibodies of this invention are used in immunoassays to detect the antigen 30 specific T-cell receptor proteins in biological samples. In this method the antibodies of the present invention are contacted with a biological sample and the formation of a complex between the T-cell receptors and antibody is detected. Immunoassays of the present invention may be 35 radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme immunoassay, chemiluminescent assay,

- 27 -

immunohistochemical assay and the like. (In "Principles and Practice of Immunoassay" (1991) Christopher P. Price and David J. Neoman (eds), Stockton Press, New York, New York; Ausubel et al. (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York). Standard techniques known in the art for ELISA are described in Methods in Immunodiagnosis, 2nd Edition, Rose and Bigazzi, eds., John Wiley and Sons, New York 1980 and Campbell et al., Methods of Immunology, W.A. Benjamin, Inc., 1964, both of which are incorporated herein by reference. Such assays may be direct, indirect, competitive, or noncompetitive immunoassays as described in the art (In "Principles and Practice of Immunoassay" (1991) Christopher P. Price and David J. Neoman (eds), Stockton Pres, NY, NY; Oellirich, M. 1984. J. Clin. Chem. Clin. Biochem. 22: 895-904) Biological samples appropriate for such detection assays include mammalian tissues, melanoma and lymph nodes, pathology specimens, necropsy specimens, bone marrow, peripheral blood lymphocytes and biopsy specimens. Proteins may be isolated from biological samples by conventional methods described in (Ausubel et al., (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York).

The antibodies of this invention can be used in immunoassays to detect the specific T-cell receptors of this invention or alteration in the level of expression of T-cells carrying the melanoma specific T-cell receptors in biological samples. Examples of biological samples include, but are not limited to, mammalian tissues, such as biopsy tissue samples, such as melanoma, peripheral blood lymphocytes, bone marrow, tumor biopsies, lymph nodes, lymphoid organs and tissue samples. Examples of diseases that can be assessed by these immunoassays, include, but are not limited to, melanomas and tissues which are secondary sites for melanoma metastasis. The

- 28 -

antibodies of this invention can therefore be used in an immunoassay to diagnose, assess or prognoses a mammal afflicted with the disease.

In another embodiment, antibodies of this invention may be used to purify or enrich for T-cells carrying the receptors provided herein which recognize tumor associated antigens, in particular melanoma antigens. Immunoaffinity chromatography can be performed by conventional methods known to one skilled in the art (Ausubel et al. (eds) (1987) in "Current Protocols in Molecular Biology" John Wiley and Sons, New York, New York). Such T-cells can then be administered in a therapeutically effective amount to mammals, preferably humans either prophylactically or therapeutically. Alternatively, such methods can be used to assess the efficacy or determine the treatment regime of the mammal.

In another embodiment monoclonal antibodies or polyclonal antisera generated in animals against all or parts thereof, preferably the unique region of the T-cell receptor can be used in immunoassays. In a preferred embodiment, a peptide based on the unique regions of the antigen specific  $\alpha$  or  $\beta$  chains peptide may be conjugated to a carrier as described in (M. Bodanszky (1984) "Principles of Peptide Synthesis," Springer Verlag, New York, New York). Using conventional methods, rabbits may be immunized with the protein or peptide conjugated to carriers. The animal receives similar booster doses and antisera titer is assessed by ELISA assay. Satisfactory levels of antisera are obtained when the anti-peptide antibody titer reaches a plateau. This antibody can be used in the standard immunoassays described above.

Alternatively anti-idiotypic antibodies against T-cell receptors may be used to access the level of a specific T-cell carrying the receptors of this invention in a mammal being treated with the methods described herein.

- 29 -

The present invention provides a method of inhibiting or preventing the growth of tumor cells by exposing tumor cells to cells expressing the antigen specific T-cell receptors or chimeric receptors provided herein. The T-cell receptors of this invention which recognize or bind tumor associated antigens may also be used for either prophylactic or therapeutic purposes. When provided prophylactically, the T-cell receptor or cells into which the T-cell receptor has been introduced is provided in advance of any evidence or symptom in the mammal due to cancer, in particular melanoma. The prophylactic use of the T-cell receptors or cells into which the antigen specific T-cell receptors have been introduced, serves to prevent or attenuate cancer, in particular melanoma, in a mammal. When provided therapeutically, the T-cell receptor or cells expressing the receptors of this invention are provided at (or shortly after) the onset of the disease in the mammal. The therapeutic administration of the T-cell receptor or cells expressing those receptors serves to attenuate the disease.

Cell-based immunotherapy currently utilizes the adoptive transfer to patients of tumor specific TIL which are expanded ex vivo [Rosenberg S.A. 1992. J. Clin. Oncol., 10:80; Rosenberg S.A., et al. N. Engl. J. Med., 319:1676; Hwu P., et al. 1993. J. Exp. Med., 178:361]. T-cell specificity may be redirected by the in vitro transfer of the nucleic acid sequences encoding the tumor associated antigen specific T-cell receptors of this invention. By way of example, a heterogenous population of T-cells, such as TIL, may be made more effective by conferring anti-tumor reactivity to non-specific T-cell populations within the TIL, or clonal expansion of undifferentiated T lymphocytes.

Cells that can be genetically modified to express the antigen specific T-cell receptors provided

- 30 -

include, but is not limited to, lymphocytes, cytotoxic T-lymphocytes, hematopoietic stem cells, monocytes, stem cells, peripheral blood and natural killer cells. In a preferred embodiment of this invention T-cells can be genetically modified to express the tumor antigen specific T-cell receptors provided herein. Preferred antigen specific T-cell receptors are shown in Figures 1A-1B and Figure 2. Constructs containing all or parts of the nucleic acid sequences encoding the T-cell receptors of this invention may be introduced in T-lymphocytes by conventional methodology. By way of example such methods include, but are not limited to, calcium phosphate transfection, electroporations, lipofections, transduction by retroviruses, injection of DNA, particle bombardment and mediated gene transfer use of a retroviral vector, viral vectors, transduction by viral coculturing with a producer cell line. Preferably the construct or constructs carrying the nucleic acid sequences of the present invention are introduced into the T-cells by transduction with viral supernatant or cocultivation with a retroviral producer cell line. Examples of vectors that may be used include, but are not limited to, defective retroviral vectors, adenoviral vectors, vaccinia viral vectors, fowl pox viral vectors, or other viral vectors (Mulligan, R.C., (1993) Science 260:926-932). Eukaryotic expression vectors GLEN (Treisman, J., et al., Blood, 85:139; Morgan et al. (1992) Nucleic Acids Res. 20:1293-1299), LXSN (Miller, A.D., et al. Methods Enzymol., 217:581-599 (1993); Miller, A.D., et al. BioTechniques, 7:980-988 (1989); Miller, A.D., et al., Mol. Cell Biol., 6:2895-2902 (1986); Miller, A.D. Curr. Top. Microbiol. Immunol., 158:1-24 (1992)), and SAM-EN (Treisman, J., et al., Blood, 85:139) may also be used. Individual constructs carrying the genes encoding for the alpha and beta chains that comprise the receptor may be introduced into the T-lymphocytes or alternatively, an individual

- 31 -

construct carrying the nucleic acid sequences encoding for both the  $\alpha$  and  $\beta$  chains of the T-cell receptor may be in a single construct. Preferably, a retroviral vector, for example a vector with the murine moloney leukemia viral LTR promoting transcription of the T-cells receptor genes is used. In a preferred embodiment nonreplicating retroviral vectors are used. Alternatively, the genes can be expressed using an internal housekeeping promoter, such as that from the phosphoglycerol kinase (PGK) gene.

The  $\alpha$  and  $\beta$  chains of the T-cell receptor could either be expressed on separate retroviral vectors, or on the same retroviral vector, separated by an internal ribosomal entry site (IRES) (Treisman, J., et al., Blood, 85:139; Morgan, R.A., et al., Nucleic Acids. Res., 20:1293-1299 (1992)). Using an IRES-containing vector, allows both T-cell receptor genes to be translated from a single RNA message. Examples of where T-lymphocytes can be isolated, include but are not limited to, peripheral blood cells lymphocytes (PBL), lymph nodes, or tumor infiltrating lymphocytes (TIL), or blood. Such lymphocytes can be isolated from the individual to be treated or from a donor by methods known in the art and cultured in vitro (Kawakami, Y. et al. (1989) J. Immunol. 142: 2453-3461).

The T-cells may be incubated with a retroviral producer cell line carrying retroviral expression vectors or with viral supernatant. Viability of the lymphocytes may be assessed by conventional methods, such as trypan blue dye exclusion assay. The genetically modified lymphocytes expressing the desired melanoma specific T-cell receptor may then be administered to a mammal, preferably a human, in need of such treatment in a therapeutically effective amount. The dosing regimes or ranges of lymphocytes used in the conventional tumor infiltrating lymphocyte (TIL) therapy (Rosenberg, et al. (1994) Journal of National Cancer Institute, Vol. 86:1159

- 32 -

may be used as general guidelines for the doses or number of T-lymphocytes to be administered to mammal in need of such treatment. By way of example, a range of about  $1 \times 10^{10}$  to about  $1 \times 10^{11}$  T-cells for each cycle of therapy may be administered in the methods provided herein. Examples of how these antigen specific T-cells can be administered to the mammal include but are not limited to, intravenously, intraperitoneally or intralesionally. Parameters that may be assessed to determine the efficacy of these transduced T-lymphocytes include, but are not limited to, production of immune cells in the mammal being treated or tumor regression. Conventional methods are used to assess these parameters. Such treatment can be given in conjunction with cytokines or gene modified cells (Rosenberg, S.A. et al. (1992) Human Gene Therapy, 3: 75-90; Rosenberg, S.A. et al. (1992) Human Gene Therapy, 3: 57-73) chemotherapy or active immunization therapies. One of skill in the art will appreciate that the exact treatment schedule and dosages, or amount of T-lymphocytes to be administered may need to be optimized for a given individual.

This invention also relates to stem cells expressing chimeric receptors or T-cell receptors which recognize tumor antigens, provided herein. Chimeric receptor genes comprising a single chain Fv domain of a specific antibody and a second segment encoding at least a transmembrane and cytoplasmic domain of an immune cell such as a T-cell receptor, one of the chains from the CD3 receptor complex, an Fc receptor, CD28 receptor, or IL-2 receptor or similar cytoplasmic domains. In a preferred embodiment the chimeric receptor comprises the variable domains from monoclonal antibodies (MAb) linked to the Fc receptor-associated  $\gamma$  chain, which is capable of mediating signal transduction in T-cells (Hwu et al. (1993) Journal of Experimental Medicine 178:361-366; Esher, et al. (1993) PNAS 90 720-724; Hwu et al (1993) Journal of Immunology 150:4104 and WO 93/19163 which are herein incorporated by



- 33 -

reference.) Methods of isolating, enriching and culturing of hematopoietic stem cells are known to those skilled in the art (Tskamoto et al., U.S. Patent No. 5,061,620 and Peault, U.S. Patent No. 5,147,784 herein incorporated by reference.

Isolation of bone marrow, a source of hematopoietic stem cells, and retroviral transduction is performed by conventional methods (Bjorkstrand, B., et al., Hum. Gene Ther., 5:1279-1286 (1994); Brenner, et al., Lancet, 342:1134-1137 (1993); Brenner, M.K., et al., N.Y. Acad. Sci Gene Therapy for Neoplastic Disease (Abstract 211993), 46:711; Brenner, M.K., et al. Lancet, 341:85-86 (1993); Brenner, M.K., et al. J. Hematother, 3:33-36 (1994); Brenner, M.K., et al. J. Hematother, 2:7-17 (1993); Brenner, M., et al. Hum. Gene Ther., 5:481-499 (1994); Brenner, M.K., et al., Ann. N.Y. Acad. Sci., 716:204-14 (1994); O'Shaughnessy, J.A., et al., Hum. Gene Ther., 4:331-354 (1993); O'Shaughnessy, J.A., et al., Hum. Gene Ther., 5:891-911 (1994); Blaese, R.M., et al., Human Gene Ther., 4:521-527 (1993); Cassel, A., et al., Exp. Hematol, 21:585-591 (1993); Dunbar, C.E., et al. Ann N.Y. Acad. Sci., 716:216-24 (1994); Bodine, D.M., et al., Blood, 82:1975-1980 (1993)]. By way of example, human CD34<sup>+</sup> hematopoietic stem cells can be readily isolated from peripheral blood [Barrande C., et al. 1993. Hybridoma, 12(2):203; Kato K., and A. Radbruch. 1993. Cytometry, 14(4):384], and may be used as targets for retroviral-mediated gene transfer [Cassel A., et al. 1993. Exp. Hematol., 21(4):585; Bregni M., et al. 1992. Blood, 80:1418]. The bone marrow isolated from a mammal may be enriched for CD34<sup>+</sup> population by using an anti-CD34<sup>+</sup> monoclonal antibody. The CD34<sup>+</sup> cells may be cultured in media comprising IL-3, IL-6 and stem cell factor (SCF). The cells may be exposed to retroviral supernatant, harvested and reinfused into the mammal in need of such treatment.

- 34 -

The constructs containing the chimeric receptors or melanoma specific T-cell receptors may be introduced into the cells by conventional methodology including, but not limited to, microinjection, electroporation, viral transduction, transduction, or transfection using DEAE-dextran, lipofection, calcium phosphate, particle bombardment mediated gene transfer or direct injection of nucleic acid sequences encoding the T-cell receptors of this invention or other procedures known to one skilled in the art. In a preferred embodiment the bone marrow containing stem cells is incubated with viral supernatant or a producer cell line carrying the retroviral construct or constructs. Examples of vectors that can be used to express the chimeric receptors or melanoma antigen specific T-cell receptors of this invention include, but are not limited to retroviral vectors, vaccinia virus vectors, adenovirus vectors, herpes virus vector, fowl pox virus vector, adeno associated virus (AAV), plasmids, such as pCDNA3 (Invitrogen, San Diego, CA) or the baculovirus transfer vectors. By way of example, eukaryotic expression vectors that may be used include, but is not limited to, G1EN (Treisman, J., et al., Blood, 85:139 Morgan, et al. (1992) Nucl. Acids Res.: 20 2293-1299), LXSXN (Miller, A.D., et al. Methods Enzymol., 217:581-599 (1993); Miller, A.D., et al., BioTechniques, 7:980-988 (1989); Miller, A.D., et al. Mol. Cell. Biol., 6:2895-2902 (1986); Miller, A.D., Curr. Top. Microbiol. Immunol., 158:1-24 (1992)) or SAM-EN vectors (Treisman, J., et al. Blood, 85:139).

The stem cells carrying either the chimeric receptor or melanoma reactive T-cell receptors provided herein are administered in a therapeutically effective amount to a mammal preferably a human in need of such treatment. Preferred T-cell receptors to be used in this embodiment are shown in Figure 1A-1B and Figure 2. Parameters to evaluate in treating the mammal include, but

- 35 -

are not limited to study of differentiated hematopoietic cells for their ability to become activated by or specifically bind the antigen recognized by the introduced receptor gene, DNA analysis of peripheral blood lymphocytes and other tissues for presence of the introduced receptor gene, and immunohistochemical antibody studies of expression of the receptor gene. In addition, in vivo anti-tumor responses can be evaluated. Complete tumor eradication may require repeated treatments, combinations of intraperitoneal and intravenous therapy, or combinations with other treatment approaches. Tumor therapy using a variety of chimeric receptors or T-cell receptors targeting different antigens may also be used or necessary should antigen down-regulation or in vivo immunoselection of antigen-negative cells become evident.

The therapeutic efficiency of differentiated lymphocytes derived from stem cells transduced with the chimeric receptor gene may be enhanced by the addition of other receptor types. This invention therefore also relates to a chimeric receptor comprising an antibody variable region joined to cytoplasmic region of CD28 from a T-cell or a similar region which can provide a T-cell with costimulating signals. For example the CD28 receptor is activated by the costimulatory molecule B7 (Linsley, P.S., et al., Proc. Natl. Acad. Sci. U.S.A., 87:5031-5035 (1990); Chen, L., et al. Cell, 71:1093-1102 (1992) Stein, et al. (1994) Mol. & Cell Biol. 14:3392).

Coadministration of a chimeric receptor gene consisting of the variable regions of a monoclonal antibody joined to the cytoplasmic domains of the CD28 receptor (SCFV-CD28) may be coadministered with other chimeric receptors. With both SCFV- $\gamma$  and SCFV-CD28 receptors a T-cell could receive both TCR activation and costimulation signals upon contact with the antibody defined antigen.

This invention also relates to pharmacological compositions comprising the T-cell receptors and chimeric

- 36 -

receptors of this invention and to pharmacological compositions of cells transformed or transduced with these receptor genes. In addition, pharmacological compositions comprising expression vectors which contain the genes for the receptors are also intended to be encompassed by this invention. The formulations of the present invention, both for veterinary and for human use, comprise each component individually or as a composition as described above, together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well-known in the pharmaceutical art.

All methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.

Formulations suitable for intravenous intramuscular, subcutaneous, or intraperitoneal administration conveniently comprise sterile aqueous solutions of the active ingredient with solutions which are preferably isotonic with the blood of the recipient. Such formulations may be conveniently prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. These may be present in unit or

- 37 -

multi-dose containers, for example, sealed ampoules or vials.

The formulations of the present invention may incorporate a stabilizer. Illustrative stabilizers are polyethylene glycol, proteins, saccharide, amino acids, inorganic acids, and organic acids which may be used either on their own or as admixtures. These stabilizers are preferably incorporated in an amount of 0.11-10,000 parts by weight per part by weight of each component or the composition. If two or more stabilizers are to be used, their total amount is preferably within the range specified above. These stabilizers are used in aqueous solutions at the appropriate concentration and pH. The specific osmotic pressure of such aqueous solutions is generally in the range of 0.1-3.0 osmoles, preferably in the range of 0.8-1.2. The pH of the aqueous solution is adjusted to be within the range of 5.0-9.0, preferably within the range of 6-8. In formulating each component separately or as a composition of the present invention, anti-adsorption agent may be used.

Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved through the use of polymer to complex or absorb the proteins or their derivatives. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by ... controlled-release preparations is to incorporate the 9-cis-retinoic acid or derivatives thereof alone or in combination with antineoplastic agents thereof into particles of a polymeric material such as polyesters,

- 38 -

o

polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxy-methylcellulose or gelatin-microcapsules and poly(methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.

When oral preparations are desired, the component may be combined with typical carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others.

The administration of the compositions or of each individual component of the present invention may be for either a prophylactic or therapeutic purpose. The methods and compositions used herein may be used alone in prophylactic or therapeutic uses or in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of cancer. Alternatively the methods and compositions described herein may be used as adjunct therapy. Veterinary uses are also intended to be encompassed by this invention.

All books, articles, or patents referenced herein are incorporated by reference. The following examples illustrate to various aspects of the invention but are in no way intended to limit the scope thereof.

- 39 -

Example 1T-cell Receptor Usage by Melanoma Specific  
Clonal and Oligoclonal TIL LinesMethods and Materials

5           Generation of TIL lines and clones. TIL were generated from tumor biopsies of patients with metastatic melanoma treated at the Surgery Branch of the NCI, as previously described (Rosenberg S.A., et al. (1988) N. Engl. J. Med. 319, 1676-1680; Topalian, S. L., et al. (1987) Journal of Immunol. Methods. 102, 127-141).  
10 Briefly, tissue from surgical specimens was dissociated into single cell suspensions and cultured in complete medium (CM) consisting of either RPMI-1640 (Biofluids, Rockville, MD) with 10% human AB serum (Bio-Whittaker, Walkersville, MD) or AIM V serum free medium (Gibco  
15 Laboratories, Grand Island, NY), supplemented with 10 µg/ml of gentamicin sulfate (Bio-Whittaker, Walkersville, MD), 50 U/ml of penicillin, 146 µg/ml of L-glutamine (Gibco Laboratories, Grand Island, NY) and 6000  
20 International Units (IU)/ml of recombinant human IL-2 (rhIL-2) (provided by Cetus Corporation, Emeryville, Calif.). Growing cultures were supplemented with fresh CM every 2-3 days and cell density was maintained below  $5 \times 10^5$  cells/ml. TIL 1200 was a 45 day old bulk TIL culture used  
25 for the treatment of patient 1200 (HLA-A1,A2; B8,B44). TIL C10-1 and TIL F2-2 were isolated from 1000 T-cells/well microcultures of a tumor digest from patient 1200. TIL 5 was isolated from a 4000 lymphocytes/well microculture of a tumor digest from patient 501 (HLA-  
30 A2,A24; B18,B35). TIL F11-21 was isolated from 1 cell/well microculture of bulk TIL obtained from patient 1102 (HLA-A2,A24; B55,B62). TIL A10 was isolated from 0.3 cell/well microculture of bulk TIL obtained from patient 537 (HLA-A1,A26; B44,B70). Tumor specificity and MHC  
35 restriction of each TIL was examined by lysis of a panel of HLA matched and mismatched melanoma lines, EBV

- 40 -

transformed B cell lines, (Surgery Branch, NIH) Daudi (ATCC) and K526 (ATCC) in standard 4 hour  $^{51}\text{Cr}$  release assays (Hom, S.S., et al. (1993) Cancer Immunol. Immunother. 36, 1-8).

5           RNA isolation and cDNA synthesis. Total cellular RNA was isolated using guanidine isothiocyanate/acid-phenol method (Chomczynski, P., & Sacchi, N. (1987) Anal. Biochem. 162, 156-159) from  $1-5 \times 10^6$  TIL. For PCR, first strand cDNA was synthesized  
10 from 1-5  $\mu\text{g}$  of total RNA using oligo-dT<sub>22</sub> and Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (Gibco-BRL, Grand Island, NY) as described (Gubler, U., & Hoffman, B.J. (1983) Gene. 25, 263-269).

Generation and screening of cDNA libraries.  
15 cDNA libraries were generated for the TCR analysis of TIL 5 and TIL A10. First and second strand cDNA was synthesized from  $2\mu\text{g}$  of Poly A<sup>+</sup> RNA as described (Gubler, U., & Hoffman, B.J. (1983) Gene. 25, 263-269). Double  
20 stranded cDNA was cloned into Eco-RI sites of  $\lambda$  gt10, packaged in vitro and plated (Packagene Lambda DNA packaging system, Promega, Madison, WI). Recombinant  $\lambda$  phage were screened by plaque hybridization with  $^{32}\text{P}$  labeled TCR  $\alpha$  or  $\beta$  region probes (Nishimura, M. et al. (1994) Journal of Immunotherapy V16:85-94).  $\lambda$  clones  
25 containing TCR cDNAs were plaque purified 3 times and full length clones were identified by PCR using  $\lambda$  gt10 primers which flank the cloning site (Clonetech, Palo Alto, CA).

PCR Primers. V gene subfamily specific PCR primer sequences were designed based upon alignments of  
30 all known TCR V $\alpha$  and V $\beta$  gene sequences. All oligonucleotides were synthesized using an ABI 392 DNA/RNA synthesizer (Applied Biosystems). The  $\alpha$ ,  $\beta$  primers used for anchor PCR and the V $\alpha$  and V $\beta$  sequences and specificity controls for PCR analysis are described (Ferradini, L., et  
35 al. (1991) Eur. J. Immunol. 21, 927-933; Ferradini, L., et



- 41 -

al. (1991) Eur. J. Immunol. 21, 935-942; and Nishimura et al., 1994 Journal of Immunotherapy 16:85-94.

PCR conditions. T-cell receptor DNA fragments were amplified from cDNA using the polymerase chain reaction as described with the following modifications (Choi, Y., et al. (1989) Proc. Natl. Acad. Sci. 86, 8941-8945). Briefly, 1% of the first strand cDNA synthesized from each TIL was subjected to amplification in a 50  $\mu$ l reaction containing 1 unit of Ampli-Taq (Perkin Elmer, Norwalk, CT), 200  $\mu$ M dNTP (Pharmacia, Piscataway, NJ), 1  $\mu$ M V $\alpha$  or V $\beta$  subfamily specific primer, and 1  $\mu$ M of the corresponding C $\alpha$  or C $\beta$  constant region primer. Amplifications were performed in a Perkin Elmer 9600 DNA thermocycler (Perkin Elmer, Norwalk, CT) using the following cycle profile: 30 cycles of 92°C denaturation for 1 minute, 60°C annealing for 1 minute, and 72°C extension for 2 minutes. PCR products were separated on 2% agarose gels along with molecular size standards. Visualization of a band of the appropriate size on an ethidium bromide stained gel indicated the presence of that T-cell receptor (TCR) subfamily.

Anchor PCR. Amplification and cloning of TCR genes was performed by anchor PCR as described (Loh, E.Y., et al. (1989) Science. 243, 217-220) with a few modifications. In brief, first strand cDNA was treated with RNase H and purified over a GlassMax column (Gibco-BRL, Grand Island, NY). One tenth of the purified cDNA was dC tailed using terminal deoxynucleotide transferase (Gibco-BRL, Grand Island, NY). The amplification reaction was performed in a 50  $\mu$ l final reaction volume using 25 ng of tailed cDNA, 4 pmoles of Anchor Primer (Gibco-BRL, Grand Island, NY), 2 pmoles of either TCR C $\alpha$  (Ferradini, L., et al., (1991) Eur. J. Immunol. 21, 927-933) or C $\beta$  (Ferradini, L., et al. (1991) Eur. J. Immunol. 21, 935-942) specific primers and 0.5 units of Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT). Amplification was

- 42 -

performed for 35 cycles at 92° for 60 seconds, 54° for 60 seconds and 72° for 120 seconds followed by a 15 minute extension period at 72°.

Cloning and Sequencing. The PCR products were separated on a low melt agarose gel (Gibco-BRL, Grand Island, NY), DNA fragments were purified using the PCR DNA purification system (Promega, Madison, WI) and cloned into the T/A vector, PCR II (Invitrogen, San Diego, CA). Cloned anchor PCR products were sequenced using the dideoxynucleotide chain termination method with T7 DNA polymerase (Sequenase 2.0, USB, Cleveland, Ohio) as described in Sanger, F., et al. (1977) Proc. Natl. Acad. Sci. USA. 74, 5463-5467). The resultant sequences were analyzed using the Genetics Computer Group, Inc. software package (Deveraux, J., et al. (1984) Nucleic Acids Res. 12, 387).

Reactivity and Specificity of TIL lines. Six CD8<sup>+</sup> TIL lines were generated from four patients with metastatic melanoma. Tumor specificity was determined by assaying in vitro lysis of a panel of melanoma cell lines (Table 1). TIL-1200, TIL-5 and TIL-F2-2 were derived from HLA-A2<sup>+</sup> patients and lysed HLA-A2<sup>+</sup>, but not HLA-A2<sup>-</sup> melanomas. TIL-C10-1 and TIL-F11-21 lysed only HLA-A1<sup>+</sup> and HLA-B55<sup>+</sup> melanoma targets, respectively. TIL-A10 lysed autologous tumor and did not lyse HLA-A1<sup>+</sup> targets. Since it was not tested against allogeneic HLA-A26<sup>+</sup>, HLA-B44<sup>+</sup> and HLA-B70<sup>+</sup> targets, the restriction of TIL-A10 could not be defined. None of the TIL exhibited nonspecific lysis due to lymphokine-activated killer (LAK) or natural killer (NK) activity as demonstrated by lack of lysis of Daudi and K562.

Analysis of V gene usage by TIL lines. TCR repertoire was examined by PCR with V gene subfamily specific primers, and by sequence analysis of cloned anchor PCR products (TIL-F11-21, TIL-F2-2, TIL-C10-1, TIL-1200) or sequence analysis of clones from cDNA libraries

- 43 -

(TIL-A10, TIL-5). TCR V gene usage by the six TIL is shown in Table 2. TIL-A10 (V $\alpha$  2.2, V $\beta$  4), TIL-5 (V $\alpha$  1.1, V $\beta$  7.3), TIL-F11-21 (V $\alpha$  15, V $\beta$  15) and TIL-F2-2 (V $\alpha$  17, V $\beta$  6.5) each expressed a single V $\alpha$  and a single V $\beta$  indicating clonality. TIL-1200 expressed two V $\alpha$  (V $\alpha$  2, V $\alpha$  9) and as many as six V $\beta$  (V $\beta$  4, V $\beta$  5, V $\beta$  6, V $\beta$  13, V $\beta$  14, V $\beta$  22) chains when analyzed by PCR with V gene specific primers. However, analysis of 25 consecutive TCR $\alpha$  anchor PCR clones and 13 consecutive TCR $\beta$  anchor PCR clones identified only V $\alpha$  9 and V $\beta$  22.1. Similar analysis have shown that the frequency of TCR anchor PCR products is proportional to the frequency of each clonotype in a T-cell population (Ferradini, L., et al. (1992) Cancer Res. 52, 4649-4654). Therefore, TIL-1200 consisted predominantly of a single T-cell clone expressing V $\alpha$  9 and V $\beta$  22.1. Sequence analysis of anchor PCR clones from TIL C10-1 revealed that all 15 TCR $\beta$  cloned anchor PCR products were V $\beta$  13.6. However, sequence analysis of 20 consecutive TCR $\alpha$  anchor PCR clones revealed two V $\alpha$  genes, V $\alpha$  8.2 (11 of 20 cloned anchor PCR products) and V $\alpha$  14.1 (9 of 20 cloned anchor PCR products).

Analysis of D, J, and N diversity segment usage by TIL lines. The V-J and V-D-J junctional sequences are unique to each T-cell clonotype and contribute to TCR diversity. Occasionally, TCR rearrangements result in non functional gene products. In order to determine which TCR $\alpha$  gene contributes a functional gene product in TIL-C10-1 and to define its clonality, the V-J or the V-D-J regions of the cloned TCR genes from TIL C10-1 were sequenced (Figure 1A). All 15 TIL-C10-1 TCR $\beta$  cloned products were comprised of V $\beta$ 13.6/D $\beta$ 1.1/J $\beta$ 1.5. Both TCR $\alpha$  chains found in TIL-C10-1 were productively rearranged and used V $\alpha$ 8.2/J $\alpha$ 49 (11/20) and V $\alpha$ 14.1/J $\alpha$ 32 (9/20). However, the amino acid translation of these TCR cDNAs indicated that only the V $\alpha$ 8.2/J $\alpha$ 49 transcripts can produce functional TCR $\alpha$  chains. While the V $\alpha$ 14.1/J $\alpha$ 32 cDNA can produce a full length TCR $\alpha$

- 44 -

protein, the J region lacks the correct amino acid sequence reported for J $\alpha$ 32 and the highly conserved FGXG motif (Koop, B.F., et al. (1993) Genomics. 84, 478-493). This motif is highly conserved both among the human and the murine J $\alpha$  segments (Koop, B.F., et al. (1993) Genomics. 84, 478-493)). The FXGX motif was also found in previously described functional TCRs containing J $\alpha$  32 and in the other TCR $\alpha$  gene (V $\alpha$  8.2/J $\alpha$  49) expressed by TIL-C10-1, suggesting that it is essential for the structural integrity of TCR $\alpha$  gene products (Klein, M. H., et al. (1987) Proc. Natl. Acad. Sci. USA. 84, 6884-6888). Therefore the V $\alpha$  14.1/J $\alpha$  32/C $\alpha$  TCR transcript in TIL-C10-1 likely encoded a non functional TCR $\alpha$  chain and the TCR $\alpha$  chain encoded by V $\alpha$ 8.2/J $\alpha$ 49/C $\alpha$  was responsible for tumor recognition.

Since the CDR3 region encoded by the V-D-J and V-J junctions of the TCRs, are believed to be involved in antigen recognition, the junctions from the three HLA-A2 restricted TIL (TIL-F2-2, TIL-1200 and TIL-5) were compared (Figure 1B). TCR V $\alpha$  and J $\alpha$  genes utilized by TIL-F2-2, TIL-1200 and TIL-5 were: V $\alpha$  17/J $\alpha$  42, V $\alpha$  9/J $\alpha$  16 and V $\alpha$  1.1/J $\alpha$  49, respectively. The TCR V $\beta$ , D $\beta$  and J $\beta$  genes utilized by the HLA-A2 restricted TIL were: V $\beta$  6.5/D $\beta$  1.1/J $\beta$  1.5 (TIL-F2-2), V $\beta$  22.1/D $\beta$  2.1/J $\beta$  2.1 (TIL-1200) and V $\beta$  7.3/D $\beta$  2.1/J $\beta$  2.1 (TIL-5). No restricted V gene usage or sequence homology at the N diversity regions was detected in the TCRs from the three HLA-A2 restricted TIL.

In most prior studies, TCR V gene usage was determined in T-cells isolated from tumor biopsies or from IL-2 expanded bulk TIL cultures (Solheim, J.C., et al. (1993) J. Immunol. 150, 800-811; Nitta, T., et al. (1990) Science. 249, 672-674; Karpatti, R.M., et al. (1991) J. Immunol. 146, 2043-2051; Ferradini, L., et al. (1992) Cancer Res. 52, 4649-4654). Increases in the frequency of TCR V gene subfamilies were seen but the antitumor

- 45 -

reactivity of the T-cells bearing these receptors was unknown. Furthermore, analysis by PCR, southern blotting, or immunofluorescence alone cannot distinguish between productively and nonproductively rearranged TCRs. Thus, this type of analysis is unable to determine which TCR  $\alpha/\beta$  pair mediates melanoma antigen recognition. The TIL lines reported here are clonal in nature and specifically recognize human melanoma cells indicating the TCR clonotypes identified in these clones are responsible for in vitro lysis of melanoma targets.

In contrast to other studies which describe restricted TCR V gene usage in melanoma TIL (Solheim, J.C., et al. (1993) J. Immunol. 150, 800-811; Nitta, T., et al. (1990) Science. 249, 672-674; Sensi, M., et al. (1993) J. Exp. Med. 178, 1231-1246), the evidence presented here in this study and others (Karpati, R.M., et al. (1991) J. Immunol. 146, 2043-2051; Ferradini, L., et al. (1992) Cancer Res. 52, 4649-4654) indicates that multiple TCR V gene segments are capable of recognizing melanoma tumor associated antigens (TAA). Among the HLA-A2 restricted, melanoma specific, CTL clones that have been examined here, three different clonotypes were identified (V $\alpha$ 1.1/V $\beta$ 7.3, V $\alpha$ 9/V $\beta$ 22.1, and V $\alpha$ 17/V $\beta$ 6.5). Alignment of junctional TCR gene sequences and polypeptide sequences from these HLA-A2 restricted clonotypes, revealed no sequence homology or common structural motifs within the (complimentary determining region or N region) (CDR3). A comparison of TCR clonotypes from the five CTL clones and one oligoclonal line to four other clones which have been described finds no common TCR V gene usage and no homology within the CDR3 region (Sensi, M., et al. (1993) J. Exp. Med. 178, 1231-1246). Therefore, we find no evidence for restricted TCR V gene usage in melanoma specific CTL clones.

Three of the TIL analyzed in this study (TIL-F2-2, TIL-C10-1, TIL-1200) were isolated from a single

- 46 -

patient. TIL-F2-2 and TIL-1200 were HLA-A2 restricted while TIL-C10-1 was HLA-A1 restricted. It follows that at least two different tumor epitopes were recognized by lymphocytes within the tumor bed of this patient, one presented in the context of HLA-A1 and the other presented in the context of HLA-A2. This result is consistent with the findings that two CTL clones from a single patient are recognize different T-cell epitopes (Sensi, M., et al. (1993) J. Exp. Med. 178, 1231-1246). In addition, multiple CTL clonotypes may be derived from a single patient that recognize one or more tumor associated epitopes presented in the context of the same restriction element.

Analysis of patient 1200 has provided information relevant to the development of for immunotherapy based cancer treatment. First, expansion of individual T-cell clonotypes is dependant on the culture conditions since two independent expansions of TIL from the same tumor biopsy yielded different clonotypes (V $\alpha$ 9/V $\beta$ 22.1 T-cells in TIL 1200 and V $\alpha$ 8.2/V $\beta$ 15 and V $\alpha$ 17/V $\beta$ 6.5 T-cells in TIL C10-1 and TIL F2-2). This result suggests that the culture conditions may influence the expansion of therapeutically relevant cells. Second, patient 1200 had a partial tumor regression following treatment with TIL 1200. Therefore, it is possible that a clonal or highly oligoclonal anti-tumor CTL population can successfully treat patients with advanced cancer. Third, the antigen recognized by TIL 1200 is expressed on most melanomas since all HLA-A2<sup>+</sup> melanomas established in the Surgery Branch, NCI are lysed by this TIL.

- 47 -

Table 1. Specificity And Reactivity of Clonal And Oligoclonal TIL Lines

				% lysis <sup>a</sup> by TIL line					
	Tumor Target	HLA-A Locus	HLA-B Locus	1200 <sup>b</sup>	F2-2 <sup>b</sup>	5 <sup>c</sup>	C10-1 <sup>b</sup>	F11-21 <sup>d</sup>	A10 <sup>e</sup>
5	501	A2,A24	B18,B35	ND	ND	52	ND	9	1
	526	A2,A3	B50,B62	60	46	16	0	ND	ND
	624	A2,A3	B7,B14	68	ND	36	-2	14	ND
	1102	A2,A24	B55,62	20	42	ND	2	61	ND
	1143	A2,A11	B7,B60	67	25	ND	3	ND	ND
10	888	A1,A24	B52,B55	2	1	-2	43	57	ND
	938	A1,A24	B7,B8	8	ND	ND	55	10	ND
	397	A1,A10	B8,B62	4	ND	-2	42	13	3
	537	A1,A26	B44,B70	ND	ND	ND	ND	6	21
	586	A29, A31	B8,B44	1	1	0	-2	ND	ND
15	K562	ND	ND	3	ND	ND	10	ND	ND
	Daudi	ND	ND	11	-6	-1	-1	1	0.2
	EBV 888	A1,A24	B5,B22	2	2	2	2	7	ND
	EBV 501	A2,A24	B18,B35	6	12	10	10	7	ND

Melanoma specific reactivity was determined by standard 4 hour <sup>51</sup>Cr release assays. Percent lysis identified in bold characters was significantly different from background lysis. Melanoma lines were derived and HLA typed as previously described (Nitta, T. et al. (1990) Science 249:672-674). Specific lysis for each TIL line was performed at least twice and representative experiments are shown. ND = Not done.

<sup>a</sup>Percent lysis is shown for an effector to target ratio of 40:1 except for TIL 5 which is an effector to target ratio of 10:1.

<sup>b</sup>Derived from patient 1200 (HLA-A1,A2; B8,B44).

<sup>c</sup>Derived from patient 501 (HLA-A2,A24; B18,B35).

<sup>d</sup>Derived from patient 1102 (HLA-A2,A24; B55,B62).

<sup>e</sup>Derived from patient 537 (HLA-A1,A26; B44,B70).

- 48 -

**Table 2: TCR V Gene Usage by Melanoma Specific TIL Clones and Oligoclonal Lines.**

TIL LINE	TCR $\alpha$ Usage	TCR $\beta$ Usage	HLA Restriction
A10	V $\alpha$ 2.2 <sup>a</sup>	V $\beta$ 4	ND <sup>b</sup>
5	V $\alpha$ 1.1 <sup>c</sup>	V $\beta$ 7.3 <sup>c</sup>	A2
F2-2	V $\alpha$ 17 <sup>d</sup>	V $\beta$ 6.5 <sup>c</sup>	A2
C10-1	V $\alpha$ 8.2 <sup>f</sup> , V $\alpha$ 14.1 <sup>f</sup>	V $\beta$ 13.6 <sup>g</sup>	A1
1200 <sup>h</sup>	V $\alpha$ 9 <sup>i</sup>	V $\beta$ 22.1 <sup>j</sup>	A2
F11-21	V $\alpha$ 15 <sup>k</sup>	V $\beta$ 15 <sup>l</sup>	B55

10 <sup>a</sup>5 of five TCR $\alpha$  genes cloned into  $\lambda$ gt10 phage and sequenced corresponded to V $\alpha$ 2.2.

<sup>b</sup>Not determined. A10 lysed only autologous tumor when tested against a small panel of melanomas.

<sup>c</sup>6 of six TCR $\alpha$  and TCR $\beta$  genes cloned into  $\lambda$  phage and sequenced corresponded to V $\alpha$ 1.1, V $\beta$ 7.3 respectively.

15 <sup>d</sup>Nine of 9 cloned anchor PCR products analyzed corresponded to V $\alpha$ 17.

<sup>e</sup>ten of 10 cloned anchor PCR products analyzed corresponded to V $\beta$  6.5.

20 <sup>f</sup>Analysis of 20 consecutive, cloned anchor PCR products revealed that 11 corresponded to V $\alpha$  8.2 and 9 correspond to V $\alpha$  14.1.

<sup>g</sup>Fifteen of 15 cloned anchor PCR products analyzed corresponded to V $\beta$ 13.6.

25 <sup>h</sup>PCR with family specific primers identified 2 V $\alpha$  genes (V $\alpha$  2 and V $\alpha$  9) and 6 V $\beta$  genes (V $\beta$  4,5,6,13,14,22) genes, but analysis of anchor PCR products revealed only V $\alpha$  9 and V $\beta$  22.1.

<sup>i</sup>Twenty-five of 25 cloned anchor PCR products analyzed by PCR and confirmed by sequencing expressed V $\alpha$ 9.

30 <sup>j</sup>Thirteen of 13 cloned anchor PCR products analyzed corresponded to V $\beta$ 22.1.

<sup>k</sup>Sixteen of 16 cloned anchor PCR products analyzed corresponded to V $\alpha$ 15.

35 <sup>l</sup>Thirteen of 13 cloned anchor PCR products analyzed corresponded to V $\beta$ 15.



Example 2IDENTIFICATION OF MART-1 SPECIFIC T-cell RECEPTORSMaterials and MethodsGeneration of TIL Lines and Clones. TIL were

5 generated from tumor biopsies of 2 patients with metastatic melanoma as previously described [Rosenberg SA, et al. N. Engl. J. Med., 319:1676-1680. 1988]. Clone A42 was established by limiting dilution at 100 cells/well, with a proliferating frequency of 1:800, and clone 1E2 was  
10 established at 1 cell/well with a proliferating frequency of 1:43. The clones were cultured in round bottom microtiter plates with Interleukin-2 (IL-2) (120 International Unit(IU)/ml) in the presence of feeders (1x10<sup>5</sup> allogeneic peripheral blood lymphocytes (PBL)/well  
15 irradiated to 5000 rads) with weekly stimulation using 1x10<sup>4</sup> autologous irradiated tumor cells/well.

Cell Lines. Melanoma cell lines C32, Malme3M, breast carcinoma cell line MDA231 (ATCC, Rockville, MD), Ewing's sarcoma cell line RD-ES (M. Tsokos, NIH), COS-7 cells (W.  
20 Leonard, NIH), melanoma cell lines 397mel, 501mel, 526mel, 624mel, 677mel, 705mel, 888mel (established in the SB/NCI lab as described in Topalian SL, et al. J. Immunol., 142:3714-3724. 1989 and T2 cells [Kawakami Y, et al. J. Exp. Med., 180:347-352. 1994] were maintained in RPMI with  
25 10% FCS.

Peptide Synthesis. Peptides were synthesized by a solid phase method using a multiple peptide synthesizer (model AMS 422, Gilson Co. Inc, Worthington, OH) and purified by HPLC on a C-4 column (VYDAC, Hesperia, CA)  
30 with 0.05% trifluoroacetic acid (TFA)/water-acetonitrile. The M-series peptides are located in a hydrophobic putative transmembrane domain in MART-1 (Kawakami Y, et al. J. Exp. Med., 180:347-352. 1994). The 10-amino acid peptides M10-3 and M10-4 contain the M9-2 sequence, with  
35 M10-3 having an additional glutamic acid at its NH<sub>2</sub> terminus and M10-4 having an extra isoleucine at its COOH-

- 50 -

terminus. They are labeled as follows: M9-1 (TTAEEAAGI), M9-2 (AAGIGILTV), M10-3 (EAAGIGILTV), and M10-4 (AAGIGILTVI) (Peptides are shown in single letter code). Peptide G9-280 (YLEPGPVTA) is derived from gp100 as described [Cox AL, et al. Science, 264:716-719. 1994].

Transient Transfection. cDNAs encoding for the melanoma antigens MART-1 and gp100, or for the HLA-A2.1 molecule were cloned into the mammalian expression plasmid pcDNA3 (Invitrogen, San Diego, CA) as previously described [Kawakami Y, et al. Proc. Natl. Acad. Sci., 91:3515-3519. 1994; Kawakami Y, et al. Proc. Natl. Acad. Sci. USA., 91:6458-6462. 1994]. COS-7 cells were then transfected with vectors encoding either MART-1 or gp100 (with or without HLA-A2.1 cDNA) by the DEAE-dextran method [Seed B, et al. Proc. Natl. Acad. Sci., 84:3365-3369. 1987].

Assessment of Antigen Recognition by TIL HLA. restricted melanoma recognition by TIL was assessed with standard 5 hour <sup>51</sup>Cr release cytotoxicity assays performed using melanoma and non-melanoma cell lines as targets [Kawakami Y, et al. J. Exp. Med., 168:2183-2191. 1988]. The analysis of the ability of MART-1 or gp100 transfected COS-7 cells to stimulate IFN- $\gamma$  release from TIL was evaluated using ELISA as previously described [Gaugler B, et al. J. Exp. Med., 179:921-930. 1994]. Recognition of known antigenic peptides by TIL was assessed using T2 cells pre-incubated for 2hr with a peptide at concentrations of either 1  $\mu$ g/ml or 1 ng/ml. The ability of the peptide pulsed T2 cells to stimulate IFN- $\gamma$  release from TIL was then assessed by enzyme-linked immunosorbent assay (ELISA).

RNA isolation and Anchor PCR. Total cellular RNA was isolated from  $5 \times 10^6$  TIL using the guanidine isothiocyanate/acid phenol method [Chomczynski P, et al. Anal. Biochem., 162:156-159. 1987]. For PCR, first strand cDNA was synthesized from 1-5  $\mu$ g of total RNA using (dT)<sub>22</sub> and molony murine leukemia virus reverse transcriptase

- 51 -

(GIBCO/BRL, Gaithersburg, MD) as described [Gubler U, et al. Gene, 25: 263-269. 1983]. Amplification and cloning of TCR genes was performed by anchor PCR using 5' anchor primer as described [Loh DY, et al. Science, 243:217-220. 1989] and either 3' TCR C $\alpha$  - (CCTCAGCTGGACCACAGC) (SEQ. ID NO: 34) [Ferradini L, et al. Eur. J. Immunol., 21:927-933. 1991] or C $\beta$  (GGCAGACAGGACCCCTTG) (SEQ. ID NO: 35) [Ferradini L, et al. Eur. J. Immunol., 21:935-942. 1991] specific primers. Amplification was performed for 35 cycles at 92°C for 60 sec, 54°C for 60 sec, and 72°C for 120 sec followed by a 15 min extension period at 72°C.

Cloning and Sequencing. The PCR products were separated on a low melt agarose gel (GIBCO/BRL, Gaithersburg, MD); DNA fragments were purified using the PCR DNA purification system (Promega, Madison WI) and cloned into the T/A vector PCR II (Invitrogen, San Diego, CA). Cloned anchor PCR products were sequenced using the dideoxynucleotide chain-termination method with T7 DNA polymerase (Sequenase 2.0, USB, Cleveland, Ohio) as described [Sanger F, et al. Proc. Natl. Acad. Sci., 74: 5463-5467. 1977]. The resultant sequences were analyzed using the Genetics Computer Group Inc., software package [Deveraux J, Nucleic Acids Res., 12:387-395. 1984].

Reactivity and Specificity of Clonal TIL Lines. Monoclonal CD8<sup>+</sup> TIL lines were generated from two HLA-A2+ patients with metastatic melanoma and tested extensively in multiple assays (thus Table 3 is representative). Clones A42 (Table 3) and 1E2 (Table 3) lysed a variety of HLA-A2+ melanoma cell lines and did not lyse HLA-A2<sup>-</sup> melanoma lines. Non-melanoma HLA-A2+ cell lines including the breast cancer cell line MDA231 and Ewing's sarcoma cell line RD-ES were not lysed in separate cytotoxicity assays performed for both clones. These clones, therefore, appeared to specifically recognize allogeneic melanoma cell lines in an HLA-A2 restricted manner and both showed identical recognition profiles.

- 52 -

Transient transfection into COS-7 cells of the expression vector pcDNA3 containing cDNA for either MART-1 or gp100, along with the HLA-A2.1 gene, was performed to elucidate if either melanoma TAA was being recognized by the T-cell clones. Reactivity of TIL towards the COS-7 cells was then evaluated by measuring IFN- $\gamma$  release. Both clones demonstrated specific reactivity towards MART-1<sup>+</sup>/HLA-A2.1<sup>+</sup> COS-7 cells (Table 4). Uncloned TIL cultures known to recognize either gp100 (TIL 1200), MART-1 (TIL 501), or both (TIL 1143) were used as positive controls [Kawakami Y, et al. Proc. Natl. Acad. Sci., 91:3515-3519. 1994; Kawakami Y, et al. J. Exp. Med., 180:347-352. 1994]. Both clones, therefore seemed to recognize the MART-1 antigen expressed by melanoma cell lines.

To test whether the two clones recognized the same or different epitopes in the MART-1 antigen, A42 and 1E2 were stimulated with T2 cells preincubated with different MART-1 (M9-1, M9-2, M10-3, M10-4) or gp100 (G9-280) peptides. As shown in Table 5, both clones specifically released IFN- $\gamma$  in response to M9-2 and M10-3 pulsed T2 cells (in a pattern similar to uncloned TIL lines 1235 and 660 which are known have MART-1 reactivity). The amount of IFN- $\gamma$  released was greatest in response to M9-2 for both clones, and greater than the bulk TIL response. This response could also be demonstrated for both peptides after a thousand fold dilution of peptide pulsed on the T2 cells.

Analysis of the TCR  $\alpha$  and  $\beta$  gene usage by Clones A42 and 1E2. To determine which TCR  $\alpha$  and  $\beta$  genes contribute a functional gene product, and to confirm T-cell clonality, the V-J or the V-D-J regions of the cloned TCR genes from A42 and 1E2 were sequenced. All five of the productively rearranged A42 TCR  $\beta$  cDNA clones were comprised of V $\beta$ 7.3/D $\beta$ 2.1/J $\beta$ 2.7/C $\beta$ 2, and all of the TCR  $\alpha$  chains (4 of 4) were V $\alpha$ 21/J $\alpha$ 42/C $\alpha$ . The 12 1E2 TCR  $\beta$  chain clone products were V $\beta$ 3.1/D $\beta$ 1.1/J $\beta$ 1.1/C $\beta$ 1, and the TCR  $\alpha$  chains were V $\alpha$ 25/J $\alpha$ 54/C $\alpha$  (9 of 9) (Figure 2). Amino acid

- 53 -

translation of all of these TCR cDNAs indicated that the transcripts can produce functional products. The TCR utilized by these two T-cell lines, therefore, demonstrated clonality, different V $\alpha$  and V $\beta$  gene usage, and no homology at the N diversity regions.

Prior TCR utilization studies have been unable to clearly delineate whether or not restricted TCR V gene usage is prevalent in T-cells reacting with setting of tumor specific antigen. Although increases in the frequencies of some TCR V gene subfamilies were seen, the specific TCR's responsible for antitumor reactivity were unknown. In contrast to reports of tumor reactive T-cell clones which noted restricted TCR V gene usage in melanoma [Sensi M, et al. J. Exp Med. 178:1231-1248. 1993; Sensi M, et al. J. Immunother., 12:207-211.1992], this study supports recent studies which have shown that multiple TCR V gene segments are capable of recognizing melanoma tumor associated antigens [Shilyansky J, et al. Proc. Natl. Acad. Sci., 91:2829-2833. 1994; Sensi M, et al. Melanoma Res., 194:261-271. 1991]. The analysis of TCR V gene usage by clones A42 and 1E2 presented here demonstrates that their variable and joining regions are distinct even though they recognize the same MART-1 epitope. Therefore, not only are multiple TCR V gene segments able to recognize melanoma antigens, but more than one TCR V gene is capable of recognizing the same specific antigenic peptide.

Another HLA-A2 restricted melanoma specific T-cell clone from the same patient as A42, clone 5 (Shilyansky J, et al. Proc. Natl. Acad. Sci., 91:2829-2833. 1994), utilizes the same V $\beta$  subfamily as A42 with a unique junctional region. Jurkat cells transfected with vectors encoding for clone 5 TCR, with the data demonstrating that clone 5 and A42 recognize the same epitope of MART-1 (Example 3)

- 54 -

Presented here for the time are TCR sequences which are capable of recognizing a specific epitope of a known melanoma associated antigen. Although TCR usage by melanoma specific clonal T-cell lines has been previously studied, the actual tumor antigen or antigenic epitope being recognized by the T-cell was unknown (Karpati RM, et al. J. Immunol., 146(6):2043-2051. 1991; Nitta T, et al. Science, 249:672-674. 1990; Ferradini RM, et al. Cancer Res., 52:4649-4654. 1992). In conclusion, this study is the first report of TCR sequences which are capable of recognizing a specific epitope of the MART-1 antigen. The two T-cell clones utilize distinct V-J and V-D-J regions, and so provide direct evidence that the immune system can provide more than one T-cell-receptor (TCR) capable of recognizing a specific tumor antigenic epitope.

- 55 -

**Table 3.** Lysis by CTL clones of HLA-A2<sup>+</sup> melanomas

5	Target *	HLA-A2	% Lysis by Effector Cells	
			Clone A42	LAK Cells
10	501mel	+	50	26
	526mel	+	37	40
	624mel	+	36	27
	677mel	+	47	54
	705mel	+	57	14
15	Malme3M	+	57	35
	C32	+	15	22
	397mel	-	0	43
	888mel	-	1	63

20

25

30

35

- 56 -

Table 3. (continued)

5	Target*	HLA-A2	% Lysis by Effector Cells	
			Clone 1E2	LAK Cells
	501mel	+	44	68
	526mel	+	94	94
10	624mel	+	24	24
	677mel	+	16	79
	705mel	+	45	44
15	Malme3M	+	65	65
	C32	+	6	41
	397mel	-	0	68
	888mel	-	4	34

20 \* Two separate 5-hr <sup>51</sup>Cr release assays performed at an effector/target cell ratio of 20:1 for Clones 1E2 and A42 and LAK cells. All targets shown were melanoma cell lines. Prior testing against non-melanoma cell lines demonstrated no lysis.

25

30

35



- 57 -

**Table 4.** MART-1 specificity of CTL clones

Stimulator Cell Line	Transfected cDNA	IFN- $\gamma$ Secretion (pg/ml)				
		TIL 1200	TIL 501	TIL 1143	Clone A42	Clone 1E2
COS 7	none	<10	<10	13	<10	<10
COS 7	HLA A2.1	<10	<10	23	<10	<10
COS 7	MART-1	<10	<10	90	<10	<10
COS 7	gp100	<10	<10	86	<10	<10
COS 7	HLA A2.1 + MART-1	<10	121	986	730	1341
COS 7	HLA A2.1 + gp100	451	<10	199	<10	<10

Reactivity of TIL towards COS-7 cells transiently transfected with cDNA for either MART-1 or gp100 (with or without HLA-A2.1) was evaluated by the specific release of IFN- $\gamma$ . TIL alone backgrounds have been subtracted. Uncloned TIL cell lines known to recognize either gp100 (TIL 1200), MART-1 (TIL 501), or both (TIL 1143) were used as positive controls.

- 58 -

**Table 5. MART-1 epitope specificity of CTL clones**

Stimulator Cell Line	Peptide ( $\mu$ g/ml)	IFN- $\gamma$ Secretion ( pg/ml)				
		None	TIL 1235	TIL 660	Clone A42	Clone 1B2
None	none	12	66	66	34	24
624mel	none	10	852	585	772	2701
397mel	none	12	16	27	18	29
T2	none	51	26	84	35	51
T2	M9-1 (1)	14	11	21	16	18
T2	M9-1 (0.001)	8	10	13	13	13
T2	M9-2 (1)	25	861	2328	>20000	16517
T2	M9-2 (0.001)	24	24	60	208	805
T2	M10-3 (1)	28	815	1116	765	5247
T2	M10-3 (0.001)	40	27	77	35	1369
T2	M10-4 (1)	11	24	52	22	24
T2	M10-4 (0.001)	8	11	32	12	11
T2	g9-280 (1)	15	15	1321	19	21
T2	g9-280 (0.001)	10	21	840	10	12

The ability of tumor or peptide-pulsed T2 cells to mediate IFN- $\gamma$  release from TILs was assessed via enzyme-linked immunosorbent assay. As positive controls, HLA-A2 restricted TIL 1235 and 660 recognize MART-1 or MART-1 and gp100 respectively. Prior to the assay, T2 cells were incubated for 2 h with MART-1 (M9-1, 9-2, 10-3, 10-4) or gp 100 (G9-280) peptides, 642mel and 397mel are HLA-A2-positive and -negative tumor lines, respectively.

- 59 -

Example 3

CHARACTERIZATION OF THE FUNCTIONAL  
SPECIFICITY OF CLONED T-cell RECEPTOR  
HETERODIMER RECOGNIZING THE MART-1 MELANOMA ANTIGEN

5                    Materials and Methods

Cell Lines. Melanoma cell lines 397mel, 501mel, 624mel, 888mel (established in the Surgery Branch, NCI as described [Topalian S.L., et al. 1989. J Immunol., 142:3714]) and T2 cells [Kawakami Y., et al. 1994. J. Exp. Med., 180:347] were maintained in RPMI with 10% FCS. 624mel was cloned in limiting dilution and screened via FACS analysis using HLA-A2 specific mAb BB7.2 (ATCC, Rockville MD) for high (624mel+) and MHC class I antigen negative (624mel-) clones. Jurkat T-cell line (ATCC, Rockville, MD) was maintained in DMEM with 10% FCS. Three CD8<sup>+</sup> TIL lines were generated from tumor biopsies of patients with metastatic melanoma as previously described [Rosenberg S.A. 1992. J. Clin. Oncol., 10:80]. Melanoma antigen specificity for TIL 1235 (MART-1), and 1200 (gp100) have been previously described [Kawakami Y., et al. 1994. Proc. Natl. Acad. Sci., 91:3515; Kawakami Y., et al. 1994. J. Exp. Med., 180:347].

Peptide Synthesis. Peptides were synthesized by a solid phase method using a multiple peptide synthesizer (model AMS 422, Gilson Co. Inc, Worthington, OH) and purified by HPLC on a C-4 column (VYDAC, Hesperia, CA) with 0.05% trifluoroacetic acid (TFA)/water-acetonitrile. The MART-1 series peptides are located in a hydrophobic putative transmembrane domain in MART-1 [Kawakami Y., et al. 1994. J. Exp. Med., 180:347]. The sequence of the MART-1 peptides used in this study are as follows: MART-1<sub>(22-30)</sub> (TTAEAAAGI) (SEQ. ID NO: 27), MART-1<sub>(27-35)</sub> (AAGIGILTV) (SEQ. ID NO: 28), MART-1<sub>(32-40)</sub> (ILTVILGVL) (SEQ. ID NO: 30), MART-1<sub>(26-35)</sub> (EAAGIGILTV) (SEQ. ID NO: 29), and MART-1<sub>(27-36)</sub> (AAGIGILTVI) (SEQ. ID NO: 31). The 10-amino acid

- 60 -

peptides MART-1<sub>(26-35)</sub> and MART-1<sub>(27-36)</sub> contain the 9-amino acid minimal determinant MART-1<sub>(27-35)</sub> with MART-1<sub>(26-35)</sub> having an additional glutamic acid at its NH<sub>2</sub> terminus and MART-1<sub>(27-36)</sub> having an extra isoleucine at its COOH-terminus. Peptide gp100<sub>(457-465)</sub> (LLDGTATLRL) (SEQ. ID NO: 32) and gp100<sub>(280-288)</sub> (YLEPGPVTA) (SEQ. ID NO: 33) were derived from gp100 as described [Kawakami Y., et al. 1994. Proc. Natl. Acad. Sci., 91:6458; Cox A.L., et al. 1994. Science, 264:716].

DNA Constructs. Full length TCR  $\alpha$  and  $\beta$  genes were amplified by polymerase chain reaction (PCR) from a  $\lambda$  phage TIL clone 5 cDNA library [Example 1; Shilyansky J., et al. (1994). Proc. Natl. Acad. Sci., 91:2829]. V $\alpha$ 1 5' (CTCGAGGTTTCAGCCATGCTCCTGG) (SEQ. ID NO: 36), C $\alpha$  3' (GATGGCGGAGGCAGTCTCTG) (SEQ. ID NO: 37) [Hall and Finn (1992) Biotechniques 13:241-257], V $\beta$ 7.3 5' (CTCGAGAGCATGGGCTGCAGGCTG) (SEQ. ID NO: 38), and C $\beta$ 2 3' (AAAGGATCCGAGCTAGCCTCTGGAATCCTTTC) (SEQ. ID NO: 39) primers were used for the amplification as described (Shilyansky J., et al. (1994). Proc. Natl. Acad. Sci., 91:2829). Resultant PCR DNA fragments were then cloned into the T/A vector PCR II (Invitrogen, San Diego, CA). The V $\alpha$ 1 gene was then ligated into the pCDNA3 expression vector (Invitrogen, San Diego CA) containing the neomycin resistance gene and a CMV eukaryotic promoter, and the V $\beta$ 7.3 gene was ligated into a modified pCDL expression vector containing the SR $\alpha$  promoter [Engel I., et al. Science, 256:1318]. Resultant clones were screened by PCR using TCR specific cloning primers, and sequenced using the dideoxynucleotide chain-termination method with T7 DNA polymerase (Sequenase 2.0, USB, Cleveland, Ohio) as described [Sanger F., et al. (1977). Proc. Natl. Acad. Sci., 74:5463].

FACS analysis. Jurkat T-cell receptor V $\beta$ 8 specific mAb C305.2 [Weiss A., and J.D. Stobo. 1984. J. Exp. Med., 160:1284] (courtesy A Weiss, HHMI, UCSF, San Francisco California), goat-anti-mouse IgG1 (Becton Dickenson, San

- 61 -

Jose, CA) goat anti mouse IgG-FITC (Becton Dickenson, San Jose, CA), anti-Leu-4 (CD3) (Becton Dickenson, San Jose, CA), W6/32 (anti-HLA A,B,C) (Sera-Lab, Sussex, England), and anti-TCR-1 (Becton Dickenson, San Jose, CA) were used for co-modulation experiments as previously described [Geisler C., et al. 1990. J Immunol., 145:1761]. Briefly,  $1 \times 10^6$  Jurkat transfectants were incubated for 12 hours at 37°C with or without 100  $\mu$ l of C305.2 mAb supernatant. Subsequently, the cell lines were washed 3x with FACS buffer (PBS containing 5% FCS and 0.05% Na azide) and re-stained with C305.2 to verify the down modulation of autologous TCR. Subsequent staining was performed with anti-CD3 or anti-TCR antibody to demonstrate the presence of transfected TCR heterodimers on the cell surface. HLA-A2 specific mAb BB7.2 (ATCC, Rockville MD) was used to identify high and low class I expressing tumor clones as described.

Transfections. Jurkat cells were transfected via electroporation (250 V, 800 mF) using 20  $\mu$ g of plasmid DNA (2 $\mu$ g of pCDNA3 TCR $\alpha$  neomycin selectable plasmid and 18  $\mu$ g of pCDL TCR  $\beta$  plasmid) and  $1 \times 10^7$  cells in a total volume of 250  $\mu$ l PBS. The cells were then incubated at 37°C in six well plates containing 5 ml DMEM and 10% FCS. After 12 hours, G418 (Gibco Grand Island, NY) was added at a concentration of 1 mg/ml. Four days later, viable cells were isolated over a Ficoll gradient (Organon Teknika, Durham, NC) and cultured in T-75 flasks (Nunc Inc., Napierville, ILL.). The media was then changed weekly until neomycin resistant cells grew to adequate numbers for testing (approximately  $1 \times 10^7$  cells at three weeks). Following initial selection the concentration of G418 was lowered to 400  $\mu$ g/ml. Jurkat transfectants were cloned by limiting dilution at 1 cell/well and screened for IL-2 production by ELISA as described.

Antigen recognition assays. T2 cells pre-incubated for 2 hr with peptide were washed 2x with PBS and then

- 62 -

added to effector cells at a 1:1 ratio for a total of  
1x10<sup>6</sup> cells / ml in a 48 well plate. Phorbol Myristate  
Acetate (PMA) (5 ng/ml, Sigma, St. Louis, Mo.) was added  
to wells containing Jurkat effector cells. The ability of  
the peptide pulsed T2 cells to stimulate cytokine release  
from Jurkat transfectants or TIL was then assessed by  
ELISA (RD systems, Minneapolis, Minn.). Jurkat  
transfectants were assessed for recognition of melanoma  
tumor lines by incubating with HLA-A2 positive (501mel,  
624mel+) or HLA-A2 negative (397mel, 624mel, 888mel)  
tumor cells in a 48 well plate for 12 hours at a 1:1 ratio  
for a total of 1x10<sup>6</sup> cells in 1 ml of media. TIL lines  
1235 and 1200 were used under similar conditions as  
positive controls. The ability of the tumor to stimulate  
cytokine release from Jurkat transfectants or TIL was  
then assessed by ELISA (RD systems, Minneapolis, Minn.).

Cell Surface Expression of Clone 5 TCR. Since  
Jurkat cells express endogenous TCR, and no sub-family  
specific antibodies are currently available which  
specifically stain either the  $\alpha$  or  $\beta$  chains of the clone 5  
TCR (V $\alpha$ 1, V $\beta$ 7.3), a more involved method was required to  
demonstrate the surface expression of the transfected TCR.  
Jurkat clone 5 TCR bulk transfectant cell lines, and  
transfected Jurkat clones 13 and 22, were incubated  
overnight with or without Jurkat T-cell receptor  $\beta$  chain  
specific mAb C305.2 (V $\beta$ 8) to down modulate the expression  
of endogenous TCR. The resultant cultures were then  
washed at 4°C in FACS buffer containing 0.05% azide, to  
prevent re-expression of the endogenous TCR, and stained  
with pan-specific anti-TCR-1, anti-HLA-A2, or anti-CD3  
mAbs. All of the cultures incubated with C305.2 showed  
down-modulation of the endogenous receptor as indicated by  
the lack of staining with C305.2 (Figures 3I-3L).  
Comparison of the transfected to non-transfected Jurkat  
cell lines, after down modulation of endogenous receptor  
on the cell surface, demonstrated a persistent expression  
of both CD3

- 63 -

and TCR in the clone 5 TCR transfected cell lines (Figures 3A-3D, Figures 3E-3H). Pretreatment with C305 mAb had no effect on the level of MHC class I expression on any of the Jurkat lines tested. These results demonstrated the surface expression of non-endogenous TCR in Jurkat cell lines transfected with clone 5 T-cell receptor genes (TCR).

Clone 5 TCR recognition of MART-1 peptide. TIL clone 5 previously had been shown to be capable of recognizing HLA-A2\* melanoma (Shilyansky J., et al. (1994)). Proc. Natl. Acad. Sci., 91:2829]. To date every melanoma TIL culture tested has recognized either MART-1 or gp100 antigens (or both) [Kawakami Y., et al. 1994. J. Exp. Med., 180:347]. Additionally, a MART-1 specific T-cell clone, A42, derived from the same parental TIL line as clone 5 which shares the same V $\beta$ 7.3 subfamily as the clone 5 TCR (see Example 2). Initial screening was performed to determine whether the clone 5 TCR complex expressed on the cell surface was a functional heterodimer, and to elucidate which melanoma TAA it was capable of recognizing. Jurkat bulk transfectants were stimulated with T2 cells preincubated with different MART-1 (MART-1<sub>(27-30)</sub>, MART-1<sub>(27-33)</sub>, MART-1<sub>(28-35)</sub>, MART-1<sub>(27-36)</sub> or gp100 (gp100<sub>(457-465)</sub>) peptides. TIL 1235 and TIL 1200 were used as positive controls. TIL 1235 recognized MART-1<sub>(27-30)</sub>, MART-1<sub>(27-33)</sub>, MART-1<sub>(28-35)</sub>, and TIL 1200 recognized gp100<sub>(457-465)</sub>. The ability of peptide-pulsed T2 cells to stimulate IL-2 release from Jurkat cells or GM-CSF release from TIL was then assessed by ELISA. Jurkat bulk transfectant cells were cloned by limiting dilution to isolate a pure population of Jurkat TCR+ cells with 8 of 28 clones screening positive for IL-2 production. The clones with the highest level of stimulated IL-2 production (clones 13 and 22) were chosen for use in further assays.

Jurkat clone 5 TCR transfectants specifically recognized T2 cells pulsed with the MART-1<sub>(27-33)</sub> peptide, as shown in Table 6. Jurkat clone 5 TCR+ cell line

SUBSTITUTE SHEET (RULE 26)

- 64 -

recognition patterns of MART-1<sub>(27-35)</sub> peptides were similar to several MART-1 specific TIL lines, including TIL 1235, which showed recognition of MART-1 peptides MART-1<sub>(27-35)</sub>, MART-1<sub>(26-35)</sub>, and MART-1<sub>(27-36)</sub> (Table 6) [Cox A.L., et al. 1994. Science, 264:716]. By contrast, TIL A42 (derived from the same parental TIL culture as clone 5) and TIL 1E2 were capable of recognizing MART-1 peptides MART-1<sub>(27-35)</sub>, and MART-1<sub>(26-35)</sub>, but not MART-1<sub>(27-36)</sub> (which contains the MART-1<sub>(27-35)</sub> sequence having an extra isoleucine at its COOH-terminus) [Example 2; Cole D.J., et al. 1994. Can. Res. 54:5265-5268].

Characterization of the sensitivity of peptide recognition by the monoclonal Jurkat clone 5 TCR<sup>+</sup> cell lines was performed using T2 cells pre-incubated with a MART-1 peptide diluted over a range of 50 nM to 640 pM. The concentration of peptide required to provide 50% of maximal IL-2 stimulation in the range of 50-200 nM (Figure 4). Both clones were more sensitive to peptide than the bulk cell line alone.

#### Clone 5 TCR recognition of Melanoma cell lines.

Having defined the MART-1 specificity of clone 5 TCR, the ability of Jurkat clone 5 TCR<sup>+</sup> cell lines to recognize MART-1 positive melanoma tumor cells was evaluated. Monoclonal Jurkat clone 5 TCR<sup>+</sup> cells were therefore tested for their ability to recognize HLA-A2<sup>+</sup> melanoma cell lines using the same conditions for cytokine release as the T2 cell assay. Recognition of tumor by the Jurkat cell lines did not occur (Table 7). Since the level of HLA-A2 expression and amount of MART-1 peptide available on the tumor cell surface are factors which could affect the ability of Jurkat clone 5 TCR<sup>+</sup> cells to recognize tumor, the assay conditions were altered to improve these parameters. A ten-fold increase in the number of tumor cells/well or up regulation of tumor class I expression using a 48 hr pre-incubation with IFN- $\gamma$  (verified by FACS analysis,) did not result in stimulation of Jurkat



- 65 -

signaling. Only after loading the tumor cells with relevant peptide by pre-incubating them for 2 hours with MART-1<sub>(27-35)</sub> did a modest level of recognition by the Jurkat TCR<sup>+</sup> clones occur (Table 7). Thus, in contrast to TIL, monoclonal Jurkat clone 5 TCR<sup>+</sup> cell lines are unable to recognize endogenous MART-1 antigen on HLA A2<sup>+</sup> tumor cells as well as when it is pulsed onto T2 cells.

Several melanoma tumor associated antigen have been cloned and the epitopes recognized by TIL from melanoma patients identified [Van der Bruggen P., et al. 1991. *Science*, 254:1643; Brichard V., et al. 1993. *J. Exp. Med.*, 178:489; Gaugler B., et al. 1994. *J. Exp. Med.*, 179:921; Kawakami Y., et al. 1994. *Proc. Natl. Acad. Sci.*, 91:3515; Kawakami Y., et al. 1994. *Proc. Natl. Acad. Sci.*, 91:6458; Cox A.L., et al. 1994. *Science*, 264:716]. Since TIL are a heterogenous population of T-cells and consequently, it has been difficult to identify the T-cell clonotypes within a bulk TIL which culture recognize tumor antigen and mediates the anti-tumor responses observed in vivo [Nishimura M.I., et al. (1994). *J. Immunother.*, 16:85-94).

This study is the first report of the reconstitution and characterization of a functional tumor antigen specific T-cell receptor heterodimer in an alternate cell line. The transfer of the TCR from a melanoma reactive clone (clone 5) to Jurkat cells has immortalized the tumor specific reactivity of clone 5 and allowed the determination of which TAA it recognized. Jurkat transfectants expressing the clone 5 T-cell receptor recognized the same MART-1 peptides as the bulk TIL (Table 6). Even though clones 5 and A42 were derived from the same patient, used the same V $\beta$  subfamily gene (V $\beta$ 7.3), and recognized the same MART-1 9-mer (MART-1<sub>(27-35)</sub>) [Example 3; Cole et al (1994) *Cancer Research*, 54:5265-5261], they had slightly different fine specificity. While both clones recognized the MART-1 10-mer, MART-1<sub>(26-35)</sub>, only clone 5

- 66 -

recognized MART-1<sub>(27-36)</sub> (both 10-mers contain the core MART-1<sub>(27-35)</sub> minimal determinant with MART-1<sub>(26-35)</sub> having an extra glutamic acid at its NH2 terminus and MART-1<sub>(27-36)</sub> having an extra isoleucine at its COOH-terminus). Given the limited ability to expand tumor specific T-cell clones, transfer of TCR genes into Jurkat cells may provide a useful method to immortalize tumor reactive T-cell clones in order to identify and characterize the fine specificity of these clones.

Stimulation of clone 5 Jurkat cells by MART-1<sub>(27-35)</sub> pulsed T2 cells but not by melanoma cells indicated that there is more to T-cell activation than the TCR-peptide-MHC interaction. The level of antigenic peptide on the surface of the tumor cell appears to be important in recognition of melanoma antigens since HLA-A2<sup>+</sup> melanoma cells were able to stimulate the clone 5 Jurkat cells only after preincubation with the MART-1<sub>(27-35)</sub> peptide (Table 7). However, the low level of IL-2 release by peptide pulsed tumor cells relative to peptide pulsed T2 cells suggests that peptide levels alone cannot completely account for the inability of tumor cells to stimulate the Jurkat transfectants. Furthermore, the peptide concentration required for stimulation of the Jurkat transfectants is not very different from the concentration required to stimulate normal T-cells. T2 cells pulsed with MART-1<sub>(27-35)</sub> at concentrations as low as 5-10 nM can stimulate our Jurkat clones to secrete IL-2 (Figure 4). Similarly, TIL clone A42 was stimulated to secrete GM-CSF by T2 cells pulsed with MART-1<sub>(27-35)</sub> at concentrations as low as 1 nM [Kawakami Y., et al. 1994. J. Exp. Med., 180:347]. Therefore, both the TIL clone and the Jurkat transfectants require similar concentrations of peptide for stimulation.

Lack of tumor cell recognition by the clone 5 Jurkat cells is more likely due to expressing a TCR derived from an MHC class I restricted, CD8<sup>+</sup> T-cell clone in CD4<sup>+</sup>

- 67 -

°

T-cell leukemia line. Lack of expression of CD8<sup>+</sup> on the Jurkat cell might account for their inability to be stimulated by tumor cells. It is also possible that T2 and melanoma cells differentially express the appropriate adhesion molecules required for efficient stimulation of the Jurkat transfectants.

10

15

20

25

30

35

TABLE 6. HUMAN CLONE 5 TCR EPITOPE MAP

Stimulator Cell Line	Peptide (2.5 umol)	Responder Cells					
		Jurkat Neo <sup>a</sup>	Jurkat bulk <sup>a</sup>	Jurkat Clone 13 <sup>a</sup>	Clone 22 <sup>a</sup>	TIL 1235 <sup>b</sup>	TIL 1200 <sup>b</sup>
None	None	<10	<10	<10	<10	<10	<10
None	MART-1 <sub>(72-80)</sub>	<10	<10	<10	<10	15	<10
None	MART-1 <sub>(77-85)</sub>	<10	<10	<10	<10	<10	22
None	MART-1 <sub>(82-90)</sub>	<10	<10	<10	<10	<10	<10
None	MART-1 <sub>(86-95)</sub>	<10	<10	<10	<10	<10	21
None	MART-1 <sub>(77-86)</sub>	<10	<10	<10	<10	<10	<10
None	gp100 <sub>(457-468)</sub>	<10	<10	<10	<10	<10	<10
T2	None	<10	<10	<10	<10	<10	21
T2	MART-1 <sub>(72-80)</sub>	<10	<10	<10	<10	21	<10
T2	MART-1 <sub>(77-85)</sub>	<10	944	1511	4760	11900	19
T2	MART-1 <sub>(82-90)</sub>	<10	<10	<10	<10	<10	<10
T2	MART-1 <sub>(86-95)</sub>	<10	695	1150	4060	6710	23
T2	MART-1 <sub>(77-86)</sub>	<10	11	84	469	614	19
T2	gp100 <sub>(457-468)</sub>	<10	<10	<10	<10	27	240

The ability of peptide-pulsed T2 cells to stimulate IL-2 release from non transfected (JRT NEO), bulk TCR clones-transfected (JRT BULK), and clone 5 TCR and clonal transfectant was assessed by ELISA. Prior to the assay T2 cells were incubated for 2hr with MART-1 peptides (MART-1<sub>(72-80)</sub>, MART-1<sub>(77-85)</sub>, MART-1<sub>(82-90)</sub>, MART-1<sub>(86-95)</sub>, or MART-1<sub>(77-86)</sub>) or gp100 peptide (gp100<sub>(457-468)</sub>) at a concentration of 2.5 uM. As positive controls, HLA-A2 restricted TIL 1235 and TIL 1200 which recognize MART-1 epitopes MART-1<sub>(72-80)</sub>, MART-1<sub>(86-95)</sub>, MART-1<sub>(77-86)</sub> or gp100 epitope gp100<sub>(457-468)</sub> respectively were assayed for GM-CSF release.

<sup>a</sup>IL-2 released (pg/ml)

<sup>b</sup>GM-CSF released (pg/ml)

TABLE 7. CLONE SJURKAT TCR RECOGNITION OF TUMOR

Stimulator Cell Line	Peptide (2.5 umol)	HLA A2.1	Responder Cells			
			None <sup>a</sup>	Jurkat neo <sup>a</sup>	Jurkat bulk <sup>a</sup>	Clone 22 <sup>a</sup>
None	None	N/A	<10	<10	23	49
None	MART-1 <sub>(77-101)</sub>	N/A	<10	<10	<10	66
T2	None	+	<10	31	<10	49
T2	MART-1 <sub>(77-101)</sub>	+	<10	17	1997	13502
397	None	-	12	21	<10	48
888	None	-	16	<10	<10	<10
624 <sup>+</sup>	None	-	<10	<10	<10	41
624 <sup>+</sup>	None	+	<10	<10	13	62
501	None	+	13	<10	<10	61
397	MART-1 <sub>(77-101)</sub>	-	<10	<10	<10	99
888	MART-1 <sub>(77-101)</sub>	-	20	<10	<10	75
624 <sup>+</sup>	MART-1 <sub>(77-101)</sub>	-	<10	<10	<10	14
624 <sup>+</sup>	MART-1 <sub>(77-101)</sub>	+	<10	<10	<10	428
501	MART-1 <sub>(77-101)</sub>	+	<10	<10	<10	540
						1235 <sup>b</sup>
						<10
						<10
						66
						1497
						<10
						<10
						<10
						557
						486
						<10
						35
						24
						448
						635

The ability of peptide-pulsed T2 cells to mediate cytokine release from non-transfected (JRT NEO), bulk TCR clones-transfected (JRT BULK) and clone 5 transfectant TCR + clonal (clone 13 and clone 22) Jurkat cells was assessed by ELISA. Prior to the assay T2 or tumor cells were incubated for 2hr with MART-1<sub>(77-101)</sub> peptide at a concentration of 2.5 uM. As a positive control, HLA-A2 restricted TIL 1235 which recognizes MART-1<sub>(77-101)</sub> was assayed by GM-CSF release.

<sup>a</sup>TIL-2 released (pg/ml)

<sup>b</sup>GM-CSF released (pg/ml)

- 70 -

Example 4

In Vivo Anti-Tumor Activity Of  
T-cells Redirected With Chimeric  
Antibody/T-cell Receptor Genes

5

Materials and MethodsConstruction of chimeric receptor genes.

Chimeric receptor genes composed of single chain variable regions (scFv) from monoclonal antibodies (MoAb) joined to the Fc receptor  $\gamma$  chain, which is capable of mediating T-cell receptor signal transduction (Orloff, D., et al. Nature, 347: 189-191, 1990., Letourneur, F. and Klausner, R.D. Proc Natl Acad Sci USA, 88: 8905-8909, 1991, Romeo, C., et al. Cell, 68: 889-897, 1992, Romeo, C. and Seed, B. Cell, 64: 1037-1046, 1991, Irving, B.A. and Weiss, A. Cell, 64: 891-901, 1991), were constructed as previously described (Figures 5A-5C; PCT W093/19163 Hwu, P., et al. J Exp Med, 178: 361-366, 1993, Eshhar, Z., et al. Proc Natl Acad Sci USA, 90: 720-724, 1993). Chimeric receptors derived from MOV18 (Coney, L.R., et al. Cancer Res, 51: 6125-6132, 1991, Miotti, S., et al. Int J Cancer, 39: 297-303, 1987), a MoAb which binds a 38 kD folate binding protein (FBP) highly expressed on most ovarian adenocarcinomas and Sp6 (Kohler, G. and Milstein, C., et al. Eur J Immunol, 6: 511-519, 1976, Ochi, A., Hawley, R.G., et al. Proc Natl Acad Sci USA, 80: 6351-6355, 1983), an anti-2,4,6 TNP MoAb were engineered as described (PCT W093/19163, Hwu, P., et al. J Exp Med, 178: 361-366, 1993.) (MOV- $\gamma$  and Sp- $\gamma$  receptors, respectively).

Retroviral vectors. The MOV- $\gamma$  or Sp- $\gamma$  chimeric receptor genes were cloned into the LXS<sub>N</sub> or G1EN (Hwu, P., et al. J Exp Med, 178: 361-366, 1993., Miller, A.D. and Rosman, G.J. BioTechniques, 7: 980-988, 1989) Treisman, et al. Blood (1994) retroviral backbones under the transcriptional control of the LTR from Moloney murine leukemia virus. The retroviral constructs also contained the neomycin phosphotransferase gene (Neo<sup>R</sup>) as a

- 71 -

selectable marker.

The gene encoding folate binding protein (FBP) was obtained from L. Coney (Apollon, Malvern, PA) and cloned into the LXS<sub>N</sub> retroviral backbone. The retroviral constructs were then transfected using CaPO<sub>4</sub> into the PA317 amphotropic packaging cell line as previously described (Hwu, P., et al. J Exp Med, 178: 361-366, 1993., Miller, A.D. and Buttimore, C. Mol Cell Biol, 6: 2895-2902, 1986).

Tumor transduction and cell culture. Tumor cell lines were cultured in RPMI 1640 with 10% heat-inactivated FCS and glutamine (all from Biofluids, Rockville, MD). 24JK tumor cells, a clone from the 3-methylcholanthrene-induced poorly immunogenic MCA 102 murine sarcoma (Shiloni, E., et al. Cancer Immunol Immunother, 37: 286-292, 1993, Karp, S.E., et al. J Immunol, 150: 896-908, 1993), were transduced with the FBP gene by incubation in retroviral supernatant in the presence of 8 µg/ml polybrene (Aldrich Chemical Co., Milwaukee, Wisconsin) to yield the 24JK-FBP tumor line. Media was replaced with fresh retroviral supernatant and polybrene every 12 hours for 3 days. Seventy-two hours after the final supernatant change, tumor cells were selected in 400 µg/ml of the neomycin analog G418 (Gibco, Grand Island, NY). Following G418 selection, successful transduction was demonstrated by FACS analysis of tumor cells with MOV18 MoAb.

Lymphocyte transduction and cell culture. Murine TIL, derived from the diphenylhydrazine-induced MC38 murine colon adenocarcinoma, were grown in IL-2 as described (Yang, J.C., et al. J. Biol. Resp. Modif., 9: 149-159, 1990). For retroviral transduction with MOV-γ and Sp-γ chimeric receptor genes, (to generate MOV-TIL and TNP-TIL, respectively) antigen-stimulated TIL were pelleted and resuspended at 3x10<sup>5</sup> TIL/ml in retroviral supernatant containing 30 IU/ml human recombinant IL-2 and

- 72 -

20 µg/ml protamine sulfate (Eli Lilly & Co., Indianapolis, IN). Media was partially exchanged with fresh retroviral supernatant containing IL-2 and protamine sulfate every 12 hours for 1-2 additional exposures. Forty-eight hours following the final supernatant change, TIL were selected in 0.3 mg/ml G418 for 5 days. This was followed by one week of expansion without G418, and then another 5-day selection in 0.3 to 1 mg/ml G418. Following G418 selection, successful transduction was confirmed by Northern analysis of total RNA as described (Hwu, P., et al. J Immunol, 150: 4104-4115, 1993).

mIFN γ ELISA.  $5 \times 10^5$  TIL and  $5 \times 10^5$  stimulator cells were cocultured for 24 hours at 37°C in a final volume of 1 ml RPMI with 10% FCS and 30 IU/ml of IL-2. Supernatants were then aspirated, centrifuged at 2000 rpm to remove cells, decanted and frozen at -70°C. Thawed aliquots were tested by ELISA for murine IFN γ. The ELISA employed a solid phase rat IgG<sub>2A</sub> MoAb specific for murine IFN-γ (Life Technologies, Gaithersburg, MD). After addition of either sample or recombinant IFN-γ standard, a biotinylated rat IgG<sub>1</sub> MoAb specific for IFN-γ (PharMingen, San Diego, CA) was used, followed by avidin-peroxidase. Color reaction was performed with the addition of H<sub>2</sub>O<sub>2</sub> and ABTS substrate (2,2'-Azino-bis[3-ethylbenzthiazoline-6-sulfonic acid]; Sigma Chemical Co., St. Louis, MO). The plates were then read at an OD of 405 nm.

Mice. C57BL/6 mice were obtained from Charles River (Raleigh, NC) and the Frederick Cancer Research Facility (Frederick, MD) and used at 8-16 weeks of age. Athymic nude mice were obtained from the Frederick Cancer Research Facility, maintained in laminar flow housing and used at 6 to 12 weeks of age.

Pulmonary Metastasis Tumor Therapy Model. C57BL/6 mice received 500 cGy total-body irradiation (to minimize any host anti-tumor immune response), followed by IV injection of  $5 \times 10^5$  to  $1 \times 10^6$  24JK or 24JK-FBP tumor



- 73 -

cells. On day 3, mice were treated intravenously with  $2-3 \times 10^7$  transduced or nontransduced TIL cells derived from the MC38 tumor, followed by 30,000 to 60,000 IU IL-2 i.p. three times a day for nine doses. Eleven to 16 days following initial tumor injection, mice were ear tagged and randomized and the lungs were removed; the number of pulmonary metastases was evaluated in a coded, blinded fashion as described previously (Mule, J.J., et al. Science, 225: 1487-1489, 1984). Lungs with  $>250$  metastases were scored as  $\geq 250$  because this was the largest number that could be accurately counted. Numbers presented are the mean numbers of pulmonary metastases plus or minus the standard error. The significance of differences between groups was determined with the Wilcoxin Rank Sums test. All p values are two-tailed.

Intraperitoneal tumor therapy model. IGROV-1 human ovarian cancer cells (Alberti, S., et al. Biochem Biophys Res Commun, 171: 1051-1055, 1990, Bénard, J., et al. Cancer Res, 45: 4970-4979, 1985) were adapted in vivo by serial intraperitoneal passages in nude mice until the line consistently grew as ascites. For the intraperitoneal tumor model,  $2.5 \times 10^6$  IGROV-1 fresh ascites cells were washed and injected intraperitoneally into nude mice. Three days later, the peritoneal tumor burden was evaluated in sample mice and the remainder were treated with a single intraperitoneal injection of  $1-3 \times 10^7$  nontransduced or transduced MC38 TIL cells. Mice were then ear-tagged and randomized to avoid cage-effects, and followed for survival.

Gene transfer of FBP antigen into nonimmunogenic murine sarcoma. The nonimmunogenic murine fibrosarcoma 24JK was retrovirally transduced with the gene encoding folate binding protein (FBP), the antigen recognized by MOv18. Following selection with the neomycin analog G418, FBP-transduced 24JK tumor (24JK-FBP) displayed high levels of FBP as did the human ovarian carcinoma IGROV-1 as

- 74 -

measured by FACS analysis with MOV18 (Figures 6A-6D).

In vitro function of murine TIL transduced with chimeric receptor genes. Murine TIL derived from the MC38 colon adenocarcinoma (38 TIL) were transduced with  
5 chimeric receptor genes derived from either the anti-ovarian cancer MoAb MOV18 (MOV- $\gamma$ ) or the anti-TNP MoAb Sp6 (Sp- $\gamma$ ) (Hwu, P., et al. J Exp Med, 178: 361-366, 1993;), and selected in G418. To assess in vitro activity, transduced, G418-selected TIL were co-cultured with tumor  
10 lines for 16-24 hours. Supernatants were then harvested and analyzed for mIFN- $\gamma$  by ELISA. All TIL cultures produced large amounts of mIFN- $\gamma$  when co-cultured with MC38 tumor cells (their native antigen) or in anti-CD3 coated plates. When co-cultured with IGROV-1 or 24JK-FBP  
15 tumor cells, both expressing large amounts of folate binding protein, mIFN- $\gamma$  production by MOV- $\gamma$  transduced TIL (MOV-TIL) increased by 54-fold and 14-fold, respectively, compared to MOV-TIL alone. In contrast, mIFN- $\gamma$  production by nontransduced (NV) TIL and TIL transduced with the  
20 anti-TNP Sp- $\gamma$  receptor (TNP-TIL) increased by only 2-4 fold upon co-culture with the FBP-expressing cell lines, and was not different compared to co-culture with the FBP non-expressing cell lines. None of the TIL cultures produced substantial amounts of mIFN- $\gamma$  upon co-culture  
25 with nontransduced 24JK cells or 888 human melanoma cells (Table 8). These data indicate that the MOV- $\gamma$  receptor gene can confer to murine TIL the capability to specifically recognize FBP-expressing tumor cells.

Treatment of Pulmonary Metastases. To determine  
30 whether MOV-TIL had antitumor activity in vivo, C57BL/6 mice were injected via the tail vein with  $1 \times 10^6$  24JK tumor cells that were either non-transduced or transduced with the FBP gene. Three days later, mice were treated with  $2.7 \times 10^7$  TIL, followed by 60,000 IU IL-2 every 8 hours for  
35 9 doses. Eleven days following the initial injection of tumor cells, mice were sacrificed and lung metastases were

- 75 -

counted. Only treatment with MOv-TIL in combination with IL-2 resulted in a significant reduction in lung metastases ( $p_2 < 0.0004$  compared to all other treatment groups), whereas treatment with IL-2 alone or nontransduced (NV) TIL in combination with IL-2 did not significantly reduce the number of 24JK-FBP pulmonary metastases. MOv-TIL did not reduce the number of non-transduced 24JK tumor cells (Table 9 and Figure 7), thus demonstrating their specificity for FBP-expressing tumors. These findings were corroborated in 2 replicate experiments.

Treatment of human ovarian cancer cells in nude mice. To assess whether MOv-TIL had significant in vivo activity against human ovarian carcinoma cells, nude mice were intraperitoneally implanted with  $2.5 \times 10^6$  IGROV-1 cells from fresh ascites. Three days later, mice were treated with a single i.p. injection of TIL and then followed for survival. Histopathologic evaluation of sample mice at the time of treatment revealed that significant amounts of disease were present and invading structures within the murine peritoneal cavity 3 days after tumor injection (Figure 8). Mice treated with MOv-TIL had significantly increased survival (median survival=90 days,  $p_2 < 0.002$ ) compared to mice treated with saline only, nontransduced TIL or TNP-TIL (median survivals=31, 37, 31 days respectively; Figure 9). This study was repeated with similar results.

Specific patterns of cytokine production by T-cells, such as TH1 versus TH2 cells, have been shown to dictate different immunologic responses and therapeutic outcomes (Romani, L., et al. Infect. Immun., 59: 4647-4654, 1991, Del Prete, G. and Romagnani, S. Trends. Microbiol., 2: 4-6, 1994, Reiner, S.L., et al. Science, 259: 1457-1460, 1993, Locksley, R.M. and Scott, P. Immunol Today, 12: A58-61, 1991, Street, N.E. and Mosmann, T.R. FASEB J., 5: 171-177, 1991).

- 76 -

This study demonstrated that T-cells transduced with chimeric receptor genes are active in vivo against tumor cells bearing the receptor-defined antigen. Previous studies using nontransduced murine and human TIL (Barth, R., et al. J Exp Med, 173: 647-658, 1991, Schwartzentruber, D.J., et al. J Clin Oncol, 12: 1475-1483, 1994) have correlated specific cytokine production in vitro with function in vivo against tumor cells bearing native tumor-associated antigens. The present results, using T-cells expressing chimeric receptors, also demonstrate that T-cells that are therapeutically effective in vivo specifically secrete cytokines in vitro.

Because antibody-based recognition of tumor is dependent upon expression of tumor-associated antigens, one potential escape mechanism for tumor cells is the down-regulation of antigen expression. In the present study, intraperitoneal injection of IGROV tumor cells into nude mice followed by intraperitoneal therapy with MOV-TIL resulted in a significant increase in survival. Although survival was enhanced 3-fold, all mice eventually died from tumor ascites. FACS analysis of these tumor cells showed continued presence of FBP expression, unchanged from ascites in control mice. This suggests that antigen down-regulation was not the mechanism of escape in this particular model.

An intraperitoneal tumor model is particularly appropriate for ovarian cancer, since the most common and earliest mode of dissemination of this disease in cancer patients is by exfoliation of cells that implant along the surfaces of the peritoneal cavity (Berek, J.S. Epithelial Ovarian Cancer. In: J.S. Berek and N.F. Hacker (eds.), Practical Gynecologic Oncology, pp. 327-375, Baltimore: Williams and Wilkins. 1994).

Table 8: Interferon- $\gamma$  release by MOV- $\gamma$  transduced TIL<sup>1</sup>

Responder	Stimulator [pg mlFN- $\gamma$ /ml/5x10 <sup>5</sup> cells/16 hours]					
	None	38 Tumor	24 JK	24 JK FBP	IGROV	2C11 <sup>2</sup>
None	173	261	477	189	261	1483
38 TIL NV	453	47,500	1220	1708	1642	> 50,000
38 TNP-TIL	387	34,315	946	1045	1006	> 50,000
38 MOV-TIL	299	41,195	891	4324	15,999	> 50,000

<sup>1</sup> In each ml, 5x10<sup>5</sup> TIL were cocultured for 16 hrs at 37°C with nothing, or 5x10<sup>5</sup> target cells (eg, IGROV, 888 MEL), or 2C11 (anti-CD3) antibody.

<sup>2</sup> 2C11<sup>1</sup> used at 4  $\mu$ g/ml, coated with HCO3- buffer, O.N. at 4°C.

**Table 9: Treatment of Pulmonary Metastases with MOv-TIL**

5	Tumor	Treatment	n	mean # lung metastases/mouse <sup>3</sup>	SEM
10	24JK-FBP	HBSS	8	229	18.6
		IL-2 <sup>1</sup>	10	232	11.0
		Normal TIL <sup>2</sup> + IL-2	10	195	16.3
		MOv TIL <sup>2</sup> + IL-2	7	13 <sup>4</sup>	3.0
15	24JK	HBSS	5	240	9.6
		IL-2 <sup>1</sup>	9	221	11.0
		MOv TIL <sup>2</sup> + IL-2	5	223	7.6

<sup>1</sup> IL-2 was given beginning on day 3 after tumor injection at 60,000 IU ip three times a day for nine doses.

20 <sup>2</sup>  $2.7 \times 10^7$  TIL (either unmodified or transduced with the MOv- $\gamma$  chimeric receptor) were given once on Day 3 after tumor injection and followed by systemic IL-2 given as described above.

25 <sup>3</sup> Mice were sacrificed on Day 11 after tumor injection and lung metastases were counted in a blinded fashion. Metastases which were too numerous to count are arbitrarily designated as  $\geq 250$ .

<sup>4</sup> Significantly less compared to other groups,  $p_2 < 0.0004$ .

30

35

- 79 -

Example 5Transduction of Stem Cells  
with Chimeric T-cell Receptor Genes

In order to combine the effector function of T-cells with the anti-tumor specificity of antibodies, chimeric receptor gene constructs containing the variable region domains from monoclonal antibodies (mAb) linked to the Fc receptor-associated  $\gamma$  chain, which has been shown to be capable of mediating signal transduction in T-cells were constructed. Chimeric receptor genes were made using single-chain VL/VH domains (scFv) from an anti-trinitrophenyl mAb as well as from MOv18, a mAb which binds the 38 kD folate binding protein highly expressed on most ovarian adenocarcinomas.

T-cells transduced with these chimeric receptor genes can specifically lyse and secrete cytokine in response to the antibody-defined antigen (Hwu, P., J Exp Med, 178: 361-366, 1993). MOv- $\gamma$  transduced T-lymphocytes lysed human ovarian cells and released GM-CSF upon co-culture with the ovarian cells. These Chimeric T-cell receptors have also been shown to be functional against tumors in vivo (Example 4).

The use of these chimeric antibody/T-cell receptor genes in hematopoietic stem cells is demonstrated here. Transduction of hematopoietic stem cells with chimeric receptor genes or antigen specific T-cell receptors allows for a permanent, regenerating in vivo supply of immune cells expressing the anti-tumor receptors, the generation of a wide variety of gene-modified cells (i.e. T-cells, macrophages, NK cells, and neutrophils.) and improved trafficking to tumor sites by transduced stem cells which differentiate and expand naturally in vivo. Tumor specific T-cell receptors may also be used in these methods.

Materials and Methods

Bone marrow transduction was performed as

- 80 -

described (Bodine, DM, Proc Natl Acad Sci USA 86: 8897-8901, 1989). Briefly, donor mice were injected with 5FU to increase the percentage of stem cell recovery. Forty-eight hours later, mice were sacrificed and bone marrow cells (BMC) were harvested from the femur and tibia. The BMC were then cultured for 48 hours in 200 Units/ml of IL1, IL3, IL6 and 10% Wehi supernatant. The BMC were then cocultured on irradiated, chimeric receptor retroviral producer cells for 48 hours. Nonadherent BMC were then isolated and injected intravenously into recipient mice which were lethally irradiated with 950 rad prior to injection.

Other methods of bone marrow isolation and transduction with chimeric receptors may be used, including but not limited to, the use of more purified stem cell preparations, supernatant transductions, or support of stem cells using other growth factors and cytokines.

Murine hematopoietic tissues were analyzed at several times points for several months following the reconstitution. Fresh splenocytes from reconstituted mice were co-cultured with tumor cells, and supernatants were assayed for murine IFN- $\gamma$ . In addition, splenocytes were activated with Con A, and assayed for cytokine release in a similar fashion 10 days later.

Vectors used: Two retroviral vectors expressing chimeric receptor genes have been utilized (Figure 10). In one, the chimeric receptor gene is under the transcriptional control of the MMLV LTR. In the other vector, the pgk housekeeping gene promoter was used to ensure in vivo expression. In the data presented, a chimeric receptor gene (MOV- $\gamma$ ) derived from an anti-ovarian cancer monoclonal antibody was utilized, which binds to a folate binding protein (FBP) which is overexpressed on most ovarian adenocarcinomas. Chimeric receptors against other antigens may be used as well. In



- 81 -

addition, other retroviral vector systems, AAV vectors (Muzyczka, N. Curr. Top. Microbiol. Immunol., 158: 97-129, 1992), gene particle bombardment, or a variety of other gene transduction systems may be used to insert the recombinant constructs into the cells.

Northern: Northern blot analysis of total RNA from splenocytes, bone marrow cells, and thymocytes of reconstituted mice showed that those cells were positive for expression of the chimeric receptor gene.

Cytokine release: Fresh splenocytes derived from 3 normal mice and 3 MOv- $\gamma$  reconstituted mice were cocultured with murine tumor cells. Murine tumor cells used were 24 JK non immunogenic methyl cholanthrene (MCA) induced sarcoma cells transduced to express the costimulatory molecule B7-1, or the folate binding protein (FBP) recognized by MOv-18 or both the B7-1 and FBP proteins. Significant levels of murine IFN- $\gamma$  were detected from MOv- $\gamma$  splenocytes cocultured with 24JK B7-FBP cells (Table 10). Significant cytokine secretion by fresh MOv- $\gamma$  spleenocytes was not seen upon co-culture with 24 JK cells expressing the FBP protein alone. Therefore, both B7 and FBP expression may be necessary for stimulation of fresh splenocytes from MOv- $\gamma$  reconstituted mice. ConA stimulation was done as a positive control.

Activated splenocytes (Table 11) from MOv- $\gamma$  reconstituted mice were capable of producing murine IFN- $\gamma$  in response to both 24JK FBP and 24JK B7-FBP cells. Thus, stimulation of activated splenocytes from MOv- $\gamma$  reconstituted mice seems to be independent of B7 expression on the target cells.

Fresh splenocytes required the expression of both B7 and the specific antigen on tumor cells for stimulation, as measured by mIFN- $\gamma$  release. Because tumor cells do not normally express B7 on their surface, further additions may be added for the chimeric receptor to function in naive splenocytes derived from transduced bone

- 82 -

marrow cells. For example, because B7 works by stimulating the CD28 receptor on T-cells, a chimeric receptor that uses the scFv antibody region joined to the CD28 signaling chain may be used in conjunction with the other chimeric receptors. T-cells expressing both the scFv- $\gamma$  and scFv-CD28 receptors would provide both TCR stimulation and costimulation signals upon antigen binding. Since activated splenocytes did not require B7 for stimulation an alternative approach in patients may include ex vivo activation of peripheral blood lymphocytes following bone marrow transplant with the transduced stem cells.

These studies show that hematopoietic bone marrow cells can be stably modified genetically with chimeric T-cell receptors, and that their progeny can be redirected against new antigens, defined by monoclonal antibodies. Examples of disease that may be treated by the immune cells derived from stem cells transduced with chimeric receptors include but are not limited to cancers, such as melanoma and ovarian cancer. Other diseases, including but not limited to, infectious diseases such as HIV, bacterial infections, or fungal infection may also be treated with the stem cells transduced with chimeric receptors or native T-cell receptors.

Alternatively, the antigen specific T-cell receptors of this invention, preferably the melanoma specific T-cell receptors may be introduced into the stem cells by retroviral transduction and used to treat mammals afflicted with a disease, therapeutically or prophylactically. Immunotherapy employing stem cells expressing antigen specific T-cell receptors against viral or bacterial antigens or parasites may also be used in the methods described herein.

- 83 -

**Table 10.** Fresh Splenocytes from pgk MOv- $\gamma$  Reconstituted Mice Release mIFN- $\gamma$  upon Stimulation with Tumors Expressing Both B7 and FBP

Responder	Stimulator [pg/ $1.5 \times 10^6$ splenocytes/ml/48hrs]					
	None	24JK NV	24JK FBP	24JK B7	24JK B7-FBP	ConA
None	76	17	4	166	26	0
NV-1	41	268	158	162	92	12,071
NV-2	50	127	96	103	63	13,916
NV-3	30	96	37	166	193	12,909
MOv- $\gamma$ 1	19	98	95	27	902	13,664
MOv- $\gamma$ 2	48	319	48	106	1078	11,584
MOv- $\gamma$ 3	76	188	65	157	1064	12,794

•  $1.5 \times 10^6$  splenocytes +  $5 \times 10^5$  tumor cells/ml  
cocultured for 48 hours.

**Table 11.** Activated Splenocytes from pgk MOv- $\gamma$  Reconstituted Mice Release mIFN- $\gamma$  upon Stimulation with FBP-Expressing Tumors

Responder	Stimulator [pg/ $1.5 \times 10^6$ splenocytes/ml/18hrs]					
	None	24JK NV	24JK FBP	24JK B7	24JK B7-FBP	ConA
None	0	0	0	0	0	0
NV-1	252	27	36	54	64	6376
NV-2	108	68	67	58	85	1988
NV-3	8	60	0	82	0	1388
MOv- $\gamma$ 1	64	101	1249	93	2289	2797
MOv- $\gamma$ 2	144	130	1377	234	1804	8541
MOv- $\gamma$ 3	143	137	2832	162	3741	<u>9096</u>

•  $1.5 \times 10^6$  splenocytes +  $5 \times 10^5$  tumor cells/ml  
cocultured for 18 hours.

- 85 -

Example 6Use Of Lymphocytes Expressing T-cell Receptors  
Which Recognize Melanoma Antigens For  
Therapeutically Treating Mammals Afflicted With  
Melanoma

5 T-lymphocytes expressing the T-cell receptors provided herein to the melanoma antigen may be effective in therapeutically treating mammals afflicted with melanoma. A retroviral expression vector carrying both the  $\alpha$  and  $\beta$  chain of the melanoma antigen specific T-cell  
10 receptors may be introduced into a retroviral packaging cell line. Alternatively, the alpha chain and beta chain may each be placed in a separate retroviral expression vector and introduced into the retroviral packaging cell line. By way of example T-lymphocytes are isolated from  
15 peripheral blood or melanoma tumor suspensions and cultured in vitro (Kawakami, Y. et al. (1988) J. Exp. Med. 168: 2183-2191). The T-lymphocytes or TIL are resuspended in media and exposed to retroviral supernatants (Hwu et al. (1993) J. of Immunol. 150:4104-4115. Retroviral  
20 supernatants may be supplemented with protamine sulfate and IL-2. The T-lymphocytes expressing the T-cell receptor may then be transfused into the patient in need of such treatment. The lymphocytes may be administered either intravenously, intraperitoneally or  
25 intralesionally. This treatment may be administered concurrently with other therapeutic treatments such as cytokines, radiotherapy, surgical excision of melanoma lesions and chemotherapeutic drugs, active immunization, adoptive T lymphocyte therapy.

30 The present invention is not to be limited in scope by the nucleic acid sequences disclosed, any sequences which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described  
35

- 86 -

herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the claims appended hereto.

5

10

15

20

25

30

35

- 87 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- (ii) TITLE OF INVENTION: T-CELL RECEPTORS AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC METHODS
- 10 (iii) NUMBER OF SEQUENCES: 39
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: MORGAN & FINNEGAN, L.L.P.  
(B) STREET: 345 PARK AVENUE  
(C) CITY: NEW YORK  
(D) STATE: NEW YORK  
15 (E) COUNTRY: USA  
(F) ZIP: 10154
- (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: FLOPPY DISK  
(B) COMPUTER: IBM PC COMPATIBLE  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: ASCII
- 20 (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: TO BE ASSIGNED  
(B) FILING DATE: 27-MARCH-1996  
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:  
25 (A) APPLICATION NUMBER: 08/411,098  
(B) FILING DATE: 27-MARCH-1995  
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: FEILER, WILLIAM S.  
(B) REGISTRATION NUMBER: 26,728  
(C) REFERENCE/DOCKET NUMBER: 2026-4188PCT
- 30 (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: (212) 758-4800  
(B) TELEFAX: (212) 751-6849  
(C) TELEX: 421792

## (2) INFORMATION FOR SEQ ID NO: 1:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 96

- 88 -

(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

## 5 (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:1:

TACTTTTGTG CAGAGAATAT GATGAACACC GGTAACCAGT 40  
TCTATTTTGG GACAGGGACA AGTTTGACGG TCATTCCAAA 80  
TATCCAGAAC CCTGAC 96

## 10 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH:108  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

## 15 (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:2:

ATGTATTTCT GTGCTTATAG GGGCCTTGGG GTGGTGCTAC 40  
AAACAAGCTC ATCTTTGGAA CTGGCACTCT GCTTGCTGTC 80  
CAGCCAAGTA CATATCCAGA ACCCTGAC 108

## 20 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 105  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

## 25 (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:3:

TACTTCTGTG CCAGCCGACC TACTATAACG GTCCCGTATA 40  
GCAATCAGCC CCAGCATTTT GGTGATGGGA CTCGACTCTC 80  
CATCCTAGAG GACCTGAACA AGGTG 105

## 30 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 98  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

## 35 (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:4:

ACCTACTTCT GTGCAGCAAG CAAGGGAGGA AGCCAAGGAA 40



- 89 -

ATCTCATCTT TGGAAAAGGC ACTAAACTCT CTGTAAACCA 80  
AATATCCAGA ACCCTGAC 98

## (2) INFORMATION FOR SEQ ID NO:5:

5

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 93  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

10

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:5:

ATGTATTACT GTGCTCTAAT CCCAGGAGGC CAGAAGCTGC 40  
TCTTTGCAAG GGGGACCATG TTAAAGGTGG ATCTTAATAT 80  
CCAGAACCT GAC 93

## (2) INFORMATION FOR SEQ ID NO:6:

15

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 93  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

20

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:6:

GAGTACTTCT GTGCTGTGGG TGCCACCGGT AACCAGTTCT 40  
ATTTTGGGAC AGGGACAAGT TTGACGGTCA TTCCAAATAT 80  
CCAGAACCT GAC 93

## (2) INFORMATION FOR SEQ ID NO:7:

25

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 108  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

30

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:7:

ATGTATCTCT GTGCCAGCAG CTTAGTAGTC TGGGACAGGG 40  
GTGGTAATCA GCCCAGCAT TTTGGTGATG GGA CTGACT 80  
CTCCATCTTA GAGGACCTGA ACAAGGTG 108

## (2) INFORMATION FOR SEQ ID NO:8:

35

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 102

- 90 -

- (B) TYPE: NUCLEOTIDE
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:8:

5 ATGTACTTCT GTGCCGCTGG GGAGACTAGC GGGGTGTCGT 40  
ACAATGAGCA GTTCTTCGGG CCAGGGACAC GGCTCACCGT 80  
GCTAGAGGAC CTGAAAAACG TG 102

(2) INFORMATION FOR SEQ ID NO:9:

- 10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 99  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:9:

15 CTGTATCTCT GTGCCAGCAG CCAAGATCTC CTGAGTTGGG 40  
ATGAGCAGTT CTTCGGGCCA GGGACACGGC TCACCGTGCT 80  
AGAGGACCTG AAAAACGTG 99

(2) INFORMATION FOR SEQ ID NO:10:

- 20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 93  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:10:

25 ATCTACTTCT GTGCTGGCCC GGGTAGCAAC TATAAACTGA 40  
CATTTGGAAA AGGAACTCTC TTAACCGTGA ATCCAAATAT 80  
CCAGAACCCT GAC 93

(2) INFORMATION FOR SEQ ID NO:11:

- 30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 99  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:11:

35 GTGTACTTCT GTGCCGCATA TTATGGAGGA AGCCAAGGAA 40  
ATCTCATCTT TGGAAAAGGC ACTAACTCT CTGTTAAACC 80

- 91 -

AAATATCCAG AACCTGAC

99

## (2) INFORMATION FOR SEQ ID NO:12:

- 5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 96  
 (B) TYPE: NUCLEOTIDE  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:12:

10 ATGTACCTCT GTGCCAGCAG TTTTGAAGGA TTGGGCACTG 40  
 AAGCTTTCTT TGGACAAGGC ACCAGACTCA CAGTTGTAGA 80  
 GGACCTGAAC AAGGTG 96

## (2) INFORMATION FOR SEQ ID NO:13:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 99  
 (B) TYPE: NUCLEOTIDE  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:13:

20 CTGTATCTCT GTGCCAGCAG CCAAGAGGGA CTAGCGGGAG 40  
 CGTCGCAGTA CTTCTGGGCCG GGCACCAGGC TCACGGTCAC 80  
 AGAGGACCTG AAAAACGTG 99

## (2) INFORMATION FOR SEQ ID NO:14:

- 25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 32  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:14:

30 Tyr Phe Cys Ala Glu Asn Met Met Asn Thr Gly Asn  
 1 5 10  
 Gln Phe Tyr Phe Gly Thr Gly Thr Ser Leu Thr Val  
 15 20  
 Ile Pro Asn Ile Gln Asn Pro Asp  
 25 30

## 35 (2) INFORMATION FOR SEQ ID NO:15:

- 92 -

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 36  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

5

- (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:15:

Met Tyr Phe Cys Ala Tyr Arg Gly Leu Gly Val Val  
 1 5 10  
 Leu Gln Thr Ser Ser Ser Leu Glu Leu Ala Leu Cys  
 15 20  
 Leu Leu Ser Ser Gln Val His Ile Gln Asn Pro Asp  
 25 30 35

- (2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 35  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

15

- (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:16:

Tyr Phe Cys Ala Ser Arg Pro Thr Ile Thr Val Pro  
 1 5 10  
 Tyr Ser Asn Gln Pro Gln His Phe Gly Asp Gly Thr  
 15 20  
 Arg Leu Ser Ile Leu Glu Asp Leu Asn Lys Val  
 25 30 35

- (2) INFORMATION FOR SEQ ID NO:17:

25

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 33  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

- (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:17:

30

Thr Tyr Phe Cys Ala Ala Ser Lys Gly Gly Ser Gln  
 1 5 10  
 Gly Asn Leu Ile Phe Gly Lys Gly Thr Lys Leu Ser  
 15 20  
 Val Lys Pro Asn Ile Gln Asn Pro Asp  
 25 30

35

- (2) INFORMATION FOR SEQ ID NO:18:

- 93 -

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 31  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

5

- (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:18:

Met Tyr Tyr Cys Ala Leu Ile Pro Gly Gly Gln Lys  
 1 5 10  
 Leu Leu Phe Ala Arg Gly Thr Met Leu Lys Val Asp  
 15 20  
 Leu Asn Ile Gln Asn Pro Asp  
 10 25 30

- (2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 31  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

15

- (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:19:

Glu Tyr Phe Cys Ala Val Gly Ala Thr Gly Asn Gln  
 1 5 10  
 Phe Tyr Phe Gly Thr Gly Thr Ser Leu Thr Val Ile  
 15 20  
 Pro Asn Ile Gln Asn Pro Asp  
 25 30

- (2) INFORMATION FOR SEQ ID NO:20:

25

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 36  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

- (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:20:

30

Met Tyr Leu Cys Ala Ser Ser Leu Val Val Trp Asp  
 1 5 10  
 Arg Gly Gly Asn Gln Pro Gln His Phe Gly Asp Gly  
 15 20  
 Thr Arg Leu Ser Ile Leu Glu Asp Leu Asn Lys Val  
 25 30 35

35

- (2) INFORMATION FOR SEQ ID NO:21:

- 94 -

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 34  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

5

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:21:

Met Tyr Phe Cys Ala Ala Gly Glu Thr Ser Gly Val  
 1 5 10  
 Ser Tyr Asn Glu Gln Phe Phe Gly Pro Gly Thr Arg  
 15 20  
 10 Leu Thr Val Leu Glu Asp Leu Lys Asn Val  
 25 30

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 33  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

15

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:22:

Leu Tyr Leu Cys Ala Ser Ser Gln Asp Leu Leu Ser  
 1 5 10  
 20 Trp Asp Glu Gln Phe Phe Gly Pro Gly Thr Arg Leu  
 15 20  
 Thr Val Leu Glu Asp Leu Lys Asn Val  
 25 30

25 (2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 31  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

30

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:23:

Ile Tyr Phe Cys Ala Gly Pro Gly Ser Asn Tyr Lys  
 1 5 10  
 Leu Thr Phe Gly Lys Gly Thr Leu Leu Thr Val Asn  
 15 20  
 Pro Trp Ile Gln Asn Pro Asp  
 25 30  
 35

- 95 -

## (2) INFORMATION FOR SEQ ID NO:24:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:24:

Val Tyr Phe Cys Ala Ala Tyr Tyr Gly Gly Ser Gln  
 1 5 10  
 Gly Trp Leu Ile Phe Gly Lys Gly Thr Lys Leu Ser  
 15 20  
 Val Lys Pro Asn Ile Gln Asn Pro Asp  
 25 30

## (2) INFORMATION FOR SEQ ID NO:25:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:25:

Met Tyr Leu Cys Ala Ser Ser Phe Glu Gly Leu Gly  
 1 5 10  
 Thr Glu Ala Phe Phe Gly Gln Gly Thr Arg Leu Thr  
 15 20  
 Val Val Glu Asp Leu Asn Lys Val  
 25 30

## (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33  
 (B) TYPE: AMINO ACID  
 (C) STRANDEDNESS: UNKNOWN  
 (D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:26:

Leu Tyr Leu Cys Ala Ser Ser Gln Glu Gly Leu Ala  
 1 5 10  
 Gly Ala Ser Gln Tyr Phe Gly Pro Gly Thr Arg Leu  
 15 20  
 Thr Val Thr Glu Asp Leu Lys Trp Val  
 25 30

- 96 -

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 9  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:27:

10 Thr Thr Ala Glu Glu Ala Ala Gly Ile  
1 5

## (2) INFORMATION FOR SEQ ID NO:28:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 9  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:28:

20 Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5

## (2) INFORMATION FOR SEQ ID NO:29:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 10  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:29:

30 Glu Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:30:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 9  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

## (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:30:



- 97 -

Ile Leu Thr Val Ile Leu Gly Val Leu  
1 5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:31:

Ala Ala Gly Ile Gly Ile Leu Thr Val Ile  
1 5 10

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:32:

Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu  
1 5 10

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 9  
(B) TYPE: AMINO ACID  
(C) STRANDEDNESS: UNKNOWN  
(D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:33:

Tyr Leu Glu Pro Gly Pro Val Thr Ala  
1 5

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18  
(B) TYPE: NUCLEOTIDE  
(C) STRANDEDNESS: SINGLE  
(D) TOPOLOGY: UNKNOWN

- 98 -

o

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:34:

CCTCAGCTGG ACCACAGC

18

5

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: NUCLEOTIDE
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: UNKNOWN

10

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:35:

GGCAGACAGG ACCCCTTG

18

(2) INFORMATION FOR SEQ ID NO:36:

15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24
- (B) TYPE: NUCLEOTIDE
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:36:

20

CTCGAGGTTC AGCCATGCTC CTGG

24

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 20
- (B) TYPE: NUCLEOTIDE
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: UNKNOWN

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:37:

30

GATGGCGGAG GCAGTCTCTG

20

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

35

- (A) LENGTH: 24
- (B) TYPE: NUCLEOTIDE
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: UNKNOWN

- 99 -

(xi) SEQUENCE DESCRIPTION:SEQ. ID NO:38:

CTCGAGAGCA TGGGCTGCAG GCTG

24

5 (2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32

(B) TYPE: NUCLEOTIDE

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: UNKNOWN

10 (xi) SEQUENCE DESCRIPTION:SEQ. ID NO:39:

AAAGGATCCG AGCTAGCCTC TGAATCCTT TC

32

15

20

25

30

35

- 100 -

We claim:

1. An isolated T-cell receptor comprising an  $\alpha$  chain, said T-cell receptor recognizing a tumor associated antigen.

2. An isolated T-cell receptor comprising a  $\beta$  chain, said T-cell receptor recognizing a tumor associated antigen.

3. An isolated T-cell receptor comprising an  $\alpha$  chain and a  $\beta$  chain, said T-cell receptor recognizing a tumor associated antigen.

4. The T-cell receptor of claims 1, 2, and 3, wherein said tumor associated antigen is an antigen expressed by tumors selected from the group consisting of melanoma, ovarian, lung, colon, kidney, breast, or prostate.

5. An isolated nucleic acid encoding at least a variable region and a joining region of an alpha chain of a T-cell receptor comprising

a variable region having a nucleic acid sequence which has a 3' end encoding for a carboxy terminus of Cysteine - Xaa<sub>n</sub>, where n may be 1-5 and Xaa may be any amino acid; and a joining region having a nucleic acid sequence selected from the group consisting of J $\alpha$  sequences shown in Figures 1A-1B, Figure 2; and a substantially homologous sequence thereof.

6. The nucleic acid sequence of claim 5 further comprising a nucleic acid sequence for a constant region.

7. The nucleic acid sequence of claim 5

- 101 -

wherein said variable region is selected from the gene group consisting of Va8.2, Va17, Va9, Va1, Va25, or Va21.

8. An isolated nucleic acid encoding a joining region for an alpha chain of a T-cell receptor, said nucleic acid having a sequence selected from the group consisting of the J $\alpha$  sequences shown in Figure 1A, Figure 1B; Figure 2; and a substantially homologous sequence thereof.

10

9. An isolated nucleic acid encoding at least a portion of the  $\beta$  chain of a T-cell receptor comprising

a variable region having a nucleic acid sequence with a 3' end encoding for a carboxy terminus of Cysteine-Xaa<sub>n</sub>, wherein n may be about 1-5 and Xaa may be any amino acid; and

15

a J region having a nucleic acid sequence selected from the group consisting of the J $\beta$  sequences shown in Figures 1A-1B, Figure 2; and a substantially homologous sequence thereof.

20

10. An isolated nucleic acid encoding a joining region for a beta chain of a T-cell receptor, said nucleic acid having sequence selected from the group consisting of the J $\beta$  sequences shown in Figures 1A-1B, Figure 2; and a substantially homologous sequence thereof.

25

11. A nucleic acid sequence encoding an  $\alpha$  chain and a nucleic acid sequence encoding  $\beta$  chain selected from the group consisting of Va 8.2/J $\alpha$  49/C $\alpha$  chain, having the V-J junctional sequences shown in Figure 1A and V $\beta$ 13.6/D $\beta$ 1.1/J $\beta$ 1.5/C $\beta$ 1 having the V-D-J junctional sequences shown in Figure 1A; Va 17/J $\alpha$ 42/C $\alpha$  having the V-J junctional sequences shown in Figure 1B and

30

35

- 102 -

°  
V $\beta$ 6.5/D $\beta$ 1.1/J $\beta$ 5.5/C $\beta$  having the V-D-J junctional sequences shown in Figure 1B; V $\alpha$ 9/J $\alpha$ 16/C $\alpha$  having the V-J junctional sequences shown in Figure 1B and V $\beta$ 22.1/D $\beta$ 2.1/J $\beta$ 2.1/C $\beta$  having the V-J-J junctional sequences shown in Figure 1B;  
5 V $\alpha$ 1/J $\alpha$ 49/C $\alpha$  having the V-J junctional sequences shown in Figure 1B; and V $\beta$ 7.3/D $\beta$ 2.6/J $\beta$ 2.1/C $\beta$ 2 having the V-D-J junctional sequences shown in Figure 1B; V $\alpha$ 25/J $\alpha$ 54/C $\alpha$  having the V-J junctional sequences shown in Figure 2 and V $\beta$ 3.1/D $\beta$ 1.1/J $\beta$ 1.1/C $\beta$ / having the V-J-J junctional sequences shown in Figure 2; and V $\alpha$ 21/J $\alpha$ 42/C $\alpha$  having the  
10 V-J junctional sequences shown in Figure 2 and V $\beta$ 7.3/D $\beta$ 2.1/J $\beta$ 2.7/C $\beta$ 2 having the V-D-J junctional sequences shown in Figure 2.

15 12. The recombinant protein produced by the nucleic acid of any one of claims 5-11.

13. Antibodies reactive with a protein according to claim 12.

20 14. An expression vector containing the nucleic acid comprising at least any one of claims 5-11.

25 15. An expression vector containing nucleic acid sequences for both  $\alpha$  and  $\beta$  chains of the T-cell receptor.

16. A host cell containing an expression vector according to claim 14.

30 17. A host cell containing an expression vector according to claim 15.

35 18. The host cell of claim 16 wherein said host cell is selected from the group consisting of T-lymphocytes, natural killer cells, monocytes, or

- 103 -

hematopoietic stem cells.

19. The host of claim 17 wherein said host is selected from the group consisting of T-lymphocytes, natural killer cells, macrocytes, or hemotopoietic stem cells.

20. A pharmaceutical composition comprising said cells of claims 16 and a pharmaceutically effective carrier.

21. A pharmaceutical composition comprising said cells of claims 17 and a pharmaceutically effective carrier.

22. A pharmaceutical composition comprising the recombinant expression vector of claim 14 and a pharmaceutically effective carrier.

23. A pharmaceutical composition comprising the recombinant expression vector of claim 15 and a pharmaceutically effective carrier.

24. A method for preventing or treating cancer in a mammal comprising administering to said mammal a therapeutically effective amount of the composition of claims 1, 20, 21, 22 or 23.

25. The method of claim 24 wherein said cancer is selected from the group consisting of lung cancer, melanoma, ovarian cancer, colon cancer, brain cancer or kidney cancer.

26. The method of claim 25 wherein said cancer is melanoma or ovarian cancer.

- 104 -

27. A nucleic acid sequence encoding a chimeric receptor comprising a variable region of an antibody joined to the cytoplasmic regions of CD28 from a T-cell or similar region which can provide costimulatory signals.

28. A recombinant protein encoded at least in part by the nucleic acid sequence of claim 27.

29. An expression vector comprising at least part of the nucleic acid of claim 26.

30. A host cell containing the expression vector according to claim 29.

31. A pharmaceutical composition comprising said expression vector of claim 29 and a pharmaceutically acceptable carrier.

32. A pharmaceutical composition comprising said host cells of claim 30 and a pharmaceutical carrier.

33. A hematopoietic stem cell containing an expression vector comprising at least part of a nucleic acid sequence encoding a chimeric receptor composed of a single chain Fv domain of a specific antibody and a second segment encoding at least a transmembrane and cytoplasmic domain of an immune cell.

34. A pharmaceutical composition comprising the cells of claim 33 and a pharmaceutically acceptable carrier.

35. A method of preventing or treating cancer in a mammal comprising administering to a mammal a therapeutically effective amount of the composition of claims 31, 32, 33, or 34.



- 105 -

36. An alpha chain of a T-cell receptor comprising at least a variable region and a joining region

5 wherein said variable region has a carboxy terminus of Cysteine - Xaa<sub>n</sub>, where n may be 1-5 and Xaa may be any amino acid; and a joining region having an amino acid sequence selected from the group of J $\alpha$  regions shown in Figures 1A-1B and Figure 2; and/or a  
10 substantially homologous sequence thereof.

37. A Beta chain of a T-cell receptor comprising at least a portion of

15 a variable region having carboxy terminus of Cysteine-Xaa<sub>n</sub>, wherein n may be about 1-5 and Xaa may be any amino acid; and

a J region having an amino acid sequence  
20 selected from the group of J $\beta$  sequences shown in Figures 1A-1B and Figure 2;  
or a substantially homologous sequence thereof.

38. An isolated T-cell receptor comprising an  $\alpha$   
25 chain and a  $\beta$  chain selected from the group consisting of V $\alpha$  8.2/J $\alpha$  49/C $\alpha$  chain, having the V-J junctional sequences shown in Figure 1A and V $\beta$ 13.6/D $\beta$ 1.1/J $\beta$ 1.5/C $\beta$ 1 having the V-D-J junctional sequences shown in Figure 1A; V $\alpha$  17/J $\alpha$ 42/C $\alpha$  having the V-J junctional sequences shown in  
30 Figure 1B and V $\beta$ 6.5/D $\beta$ 1.1/J $\beta$ 1.5/C $\beta$  having the V-D-J junctional sequences shown in Figure 1B; V $\alpha$ 9/J $\alpha$ 16/C $\alpha$  having the V-J junctional sequences shown in Figure 1B and V $\beta$ 22.1/D $\beta$ 2.1/J $\beta$ 2.1/C $\beta$ 2 having the V-J-J junctional sequences shown in Figure 1B; V $\alpha$ 1/J $\alpha$ 49/C $\alpha$  having the V-J  
35 junctional sequences shown in Figure 1B; and V $\beta$ 7.3/D $\beta$ 2.6/J $\beta$ 2.1/C $\beta$ 2 having the V-D-J junctional

- 106 -

sequences shown in Figure 1B; V $\alpha$ 25/J $\alpha$ 54/C $\alpha$  having the V-J junctional sequences shown in Figure 2 and V $\beta$ 3.1/D $\beta$ 1.1/J $\beta$ 1.1/C $\beta$  having the V-J-J junctional sequences shown in Figure 2; and V $\alpha$ 21/J $\alpha$ 42/C $\alpha$  having the V-J junctional sequences shown in Figure 2 and V $\beta$ 7.3/D $\beta$ 2.1/J $\beta$ 2.7/C $\beta$ 2 having the V-D-J junctional sequences shown in Figure 2.

39. The use of the T-cell receptors of claims 1-5 in the manufacture of a medicament for preventing or treating melanoma.

40. The use of the nucleic acid sequences of claims 5-11 in the manufacture of a medicament for preventing or treating melanoma.

41. The use of the expression vector of claims 14-15 in the manufacture of a medicament for preventing or treating melanoma.

42. The use of the nucleic acid sequence of claim 27 in the manufacture of a medicament for preventing or treating melanoma.

43. The use of the recombinant se expression vector of claim 29 in the manufacture of a medicament for preventing or treating cancer in a mammal.

44. The use of the hematopoietic stem cells of claim 33 in the manufacture of a medicament for preventing or treating cancer in a mammal.

45. The use of the proteins of claims 36-39 in the manufacture of a medicament for preventing or treating cancers in a mammal.

## FIG 1A

V gene	J region	C region
TIL C10-1 Va8.2/Jα49/Cα	TACTTTTGTGCA Y F C A	ATATCCAGAACCCCTGAC I Q N P D
TIL C10-1 Va14.1/Jα32/Cα	ATGTATTCTGTGCT M Y F C A	ATATCCAGAACCCCTGAC I Q N P D
TIL C10-1 VB13.6/DB1.1/Jβ1.5/Cβ1	TACTTCTGTGCCAGC Y F C A S	AGGACCTGAACAAGGTG D L N K V

1/12

## FIG 1B





V gene	J region	C region
TIL F2-2 Va17/Jα42/Cα	ACCTACTTCTGTGCA T Y F C A	ATATCCAGAACCCCTGAC I Q N P D
TIL 1200 Va9/Jα16/Cα	ATGTATTACTGTGCT M Y Y C A	ATATCCAGAACCCCTGAC I Q N P D
TIL 5 Va1/Jα49/Cα	CAGTACTTCTGTGCT E Y F C A	ATATCCAGAACCCCTGAC I Q N P D
TIL F2-2 VB6.5/DB1.1/Jβ1.5/Cβ1	ATGTATTCTGTGCCAGCAGC M Y L C A S S	AGGACCTGAACAAGGTG D L N K V
TIL 1200 VB22.1/DB2.1/Jβ2.1/Cβ2	ATGTACTTCTGTGCG M Y F C A	AGGACCTGAACAAGGTG D L K N V
TIL 5 VB7.3/DB2.1/Jβ2.1/Cβ2	CTGTACTTCTGTGCCAGCAGC L Y L C A S S	AGGACCTGAACAAGGTG D L K N V

2/12

## FIG. 2

	V $\alpha$ region	J $\alpha$ region	C $\alpha$ region
TIL 1E2 V $\alpha$ 25// $\alpha$ 54/C $\alpha$	ATCTACTTCTGTGCT I Y F C A	GGCCCGGTAGCAACTATAACTGACATTGGAAAGGAAGTCTCTTAACCGTGAATCCAA G P G S N Y K L T F G K G T L L T V N P N	ATATCCAGAACCCCTGAC I Q N P D
TIL A42 V $\alpha$ 21// $\alpha$ 42/C $\alpha$	GTGTACTTCTGTG V Y F C A	CCGCATATTATGGAGGAAGCCAGGAATCTCATCTTTGGAAAGGCACCTAACTCTCTTTAAACCAA A Y Y G G S Q G N L I F G K G T K L S V K P N	ATATCCAGAACCCCTGAC I Q N P D
	V $\beta$ region	J $\beta$ region	C $\beta$ region
TIL 1E2 V $\beta$ 3.1/D $\beta$ 1.1// $\beta$ 1.1/C $\beta$ 1	ATGTACCTCTGTGCCAGCACT M Y L C A S S	TTTGAAGGATTGGGCACTGAAGCTTTCTTTTGGACAAGGACCCAGACTTCACAGTTGTAG F E G L G T E A F F G Q G T R L T V V E	AGGACCTGAACAAGGTG D L N K V
TIL A42 V $\beta$ 7.3/D $\beta$ 2.1// $\beta$ 2.7/C $\beta$ 2	CTGTATCTCTGTGCCAGCAGC L Y L C A S S	CAAGAGGACTAGCGGGAGCGTCGCAGTACTTCGGGGCGGGGACCCAGGCTCACAG Q E G L A G A S Q Y F G P G T R L T V T E	AGGACCTGAACCAACGTG D L K N V

3/12

**FIG. 3A****FIG. 3B****FIG. 3C****FIG. 3D**

4/12

FIG. 3E




FIG. 3F




FIG. 3G





FIG. 3H



5/12

FIG. 3I




FIG. 3J




FIG. 3K






FIG. 3L



6/12

FIG. 4





7/12

FIG. 5A




FIG. 5C




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C





FIG. 6D



9/12

**FIG. 7**




10/12

**FIG. 8**



11/12

**FIG. 9**

12/12

FIG. 10A





FIG. 10B



# INTERNATIONAL SEARCH REPORT

International Application No

PC./US 96/04143

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/725 C07K16/28 C12N15/85 C12N5/10  
A61K35/14 A61K35/28 A61K48/00 C12N15/62 C07K19/00  
//C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 91, no. 7, 29 March 1994, WASHINGTON, DC, USA, pages 2829-2833, XP002009766 J. SHILYANSKY ET AL.: "T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines." cited in the application see abstract see figure 1 see table 2 see page 2832, right-hand column, line 15 - line 22</p>	<p>1-12, 14-26, 36-41,45</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

30 July 1996

Date of mailing of the international search report

09.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

## INTERNATIONAL SEARCH REPORT

International Application No

PC/US 96/04143

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CANCER RESEARCH, vol. 55, no. 4, 15 February 1995, BALTIMORE, MD, USA, pages 748-752, XP002009767 D. COLE ET AL.: "Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen." see abstract</p> <p>---</p>	1-26, 35-41,45
X	<p>CANCER RESEARCH, vol. 54, no. 20, 15 October 1994, BALTIMORE, MD, USA, pages 5265-5268, XP002009768 D. COLE ET AL.: "Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope." cited in the application see abstract see figure 1</p> <p>---</p>	1-12, 24-26, 36-40,45
X	<p>THE JOURNAL OF IMMUNOLOGY, vol. 154, no. 4, 15 February 1995, BALTIMORE, MD, USA, pages 1797-1803, XP002009769 R. WANG ET AL.: "Limited T cell antigen receptor repertoire in tumor-infiltrating lymphocyte and inhibition of experimental lung metastasis of murine melanoma by anti-TcR antibody." see abstract</p> <p>---</p>	1,4,39, 45
X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 90, no. 2, 15 January 1993, WASHINGTON, DC, USA, pages 720-724, XP002009770 Z. ESHHAR ET AL.: "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors." cited in the application see abstract see discussion</p> <p>---</p>	27-32, 35,42,43

-/--



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/04143

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CANCER DETECTION AND PREVENTION, vol. 18, no. 1, 1994, NEW YORK, NY, USA, pages 43-50, XP000590818 P. HWU ET AL.: "The genetic modification of T cells for cancer therapy: An overview of laboratory and clinical trials." see abstract see page 45, right-hand column, line 19 - page 47, left-hand column, line 11 ---</p>	33-35,44
X	<p>EP,A,0 203 403 (ASAHI KASEI KOGYO KK) 3 December 1986 see examples 5-10 see claims ---</p>	1-4,39
A	<p>AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 10, no. suppl. 3, September 1994, NEW YORK, NY, USA, page S117 XP000590825 S. ROSENBERG: "The gene therapy of cancer." see abstract 216 -----</p>	33-35,44

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 04143

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: X  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 24-26 and 35 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/US 96/04143

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-203403	03-12-86	JP-A- 61254527	12-11-86
		JP-A- 62010016	19-01-87
		JP-A- 62012718	21-01-87
		JP-A- 62032879	12-02-87
		DE-A- 3687014	03-12-92
-----			